prednisone has been researched along with Anemia in 253 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Excerpt | Relevance | Reference |
---|---|---|
"To test the hypothesis that combination treatment with lenalidomide and prednisone will yield a higher erythroid response rate in patients with non-del(5q) lower-risk myelodysplastic syndromes compared to the historical clinical trial data with lenalidomide monotherapy, which reported a 26% transfusion independence rate." | 9.30 | Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. ( Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S, 2019) |
"The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)." | 9.19 | Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014) |
"We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 9.16 | Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012) |
"5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia." | 9.14 | Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009) |
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia." | 7.83 | Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016) |
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia." | 7.80 | [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014) |
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)." | 7.78 | Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012) |
" An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia." | 7.74 | Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. ( Scheinfeld, N, 2007) |
"A 4-year-old, spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ following chronic immunosuppressive therapy with prednisone and cyclosporine for management of an immune-mediated nonregenerative anaemia." | 7.73 | Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. ( Callan, MB; Mauldin, E; Preziosi, D, 2005) |
"Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid." | 7.70 | Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. ( Albertioni, F; Heilborn, JD; Peterson, C; Ståhle-Bäckdahl, M; Stephansson, E; Vassilaki, I, 1999) |
"To test the hypothesis that combination treatment with lenalidomide and prednisone will yield a higher erythroid response rate in patients with non-del(5q) lower-risk myelodysplastic syndromes compared to the historical clinical trial data with lenalidomide monotherapy, which reported a 26% transfusion independence rate." | 5.30 | Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. ( Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S, 2019) |
"The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
"Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence)." | 5.19 | Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. ( Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S, 2014) |
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)." | 5.19 | Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014) |
"We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 5.16 | Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012) |
"5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia." | 5.14 | Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009) |
"Epoetin alfa administered at 40,000 U weekly parallel to BEACOPP chemotherapy was safe in patients with advanced-stage HL and reduced the number of RBC transfusions but had no impact on fatigue and other PRO domains." | 5.14 | Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. ( Borchmann, P; Diehl, V; Engert, A; Flechtner, HH; Fuchs, M; Haverkamp, H; Josting, A; Lohri, A; Nogova, L; Rank, A; Sökler, M; Sturm, I; Topp, MS; Villalobos, M; Vogelhuber, M; Zenz, T; Zijlstra, J, 2010) |
"Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0." | 5.05 | Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. ( Alcalá, A; Bueno, J; Domingo, A; Ferrán, C; García-Conde, J; Giralt, M; Montserrat, E; Parody, R; Rubio, D; Sanz, MA, 1985) |
"The effect of certain disease parameters on remission and survial time was evaluated in 482 patients with multiple myeloma treated with intermittent courses of melphalan-prednisone combinations." | 5.04 | Prognostic factors in multiple myeloma. ( Alexanian, R; Balcerzak, S; Bonnet, JD; Gehan, EA; Haut, A; Hewlett, JS; Monto, RW, 1975) |
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia." | 3.83 | Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016) |
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia." | 3.80 | [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014) |
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)." | 3.78 | Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012) |
" An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia." | 3.74 | Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. ( Scheinfeld, N, 2007) |
"A 4-year-old, spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ following chronic immunosuppressive therapy with prednisone and cyclosporine for management of an immune-mediated nonregenerative anaemia." | 3.73 | Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. ( Callan, MB; Mauldin, E; Preziosi, D, 2005) |
"Changes in hemoglobin (HGB) and serum albumin (SA) concentration associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing the values obtained on the day thalidomide or prednisone therapy commenced, with each patients' preceding values." | 3.71 | Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. ( Rea, TH, 2001) |
" While a corticosteroid treatment with prednisone (1 mg/kg/d) did not show any efficacy upon anemia, the patient's pregnancy was followed by prolonged correction of hemoglobin, making possible the tapering of prednisone down to 10 mg/d." | 3.70 | [A case of post-partum remission of acquired dyserythropoiesis, a rare cause of anemia in disseminated lupus erythematosus]. ( Debandt, M; Hayem, G; Kahn, MF; Kettaneh, A; Lebail-Darné, JL; Meyer, O; Palazzo, E; Roux, S, 1998) |
"Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid." | 3.70 | Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. ( Albertioni, F; Heilborn, JD; Peterson, C; Ståhle-Bäckdahl, M; Stephansson, E; Vassilaki, I, 1999) |
"Of the 57 patients in this phase I trial, 55 participated in 1 of 2 dosing schedules that included rituximab (375 mg/m(2)) and cyclophosphamide (750 or 1,000 mg/m(2)) administered on day 1 of each 21-day cycle and prednisone (100 mg orally) days 2 to 6." | 2.76 | Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. ( Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z, 2011) |
"Lenalidomide therapy was continued indefinitely in patients exhibiting clinical benefit." | 2.74 | Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. ( Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S, 2009) |
"Prednisone was common to all three schedules and was given daily in an initial dosage of 0." | 2.64 | Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. ( Glidewell, O; Rai, KR; Sawitsky, A; Silver, RT, 1977) |
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
"Postpartum-acquired haemophilia A is a rare but potentially severe complication of pregnancy." | 2.45 | Postpartum-acquired haemophilia A: a description of three cases and literature review. ( Prejanò, S; Santoro, RC, 2009) |
"Fever, arthritis and skin rash was constant." | 2.41 | [Adult Still's disease: study of a series of 11 cases]. ( Ben Maïz, H; Ben Taarit, C; Turki, S, 2002) |
"Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease." | 2.40 | Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation? ( Ammirati, M; Gruenstein, S; Kim, P; Korelitz, BI; Lipsey, L; Schwarz, S; Wisch, N; Zlatanic, J, 1997) |
"Proximal renal tubular acidosis (RTA) complicated with anemiawas confirmed after admission." | 1.56 | [The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis]. ( Chen, G; Li, MX; Wu, D, 2020) |
"DiGeorge syndrome is the most common chromosome microdeletion disease." | 1.43 | [Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review]. ( Guo, JQ; Hua, Y; Lu, XT; Sun, Q; Xie, Y; Zhao, WH, 2016) |
"Alveolar hemorrhage is a potentially life-threatening condition which is usually managed by the pulmonologist." | 1.43 | Severe Alveolar Hemorrhage - What's in it for the Gastroenterologist? ( Balaban, DV; Jinga, M; Jurcuţ, C; Laurila, K; Popp, A; Șotcan, M, 2016) |
"Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening dermatological conditions." | 1.42 | [Systemic lupus erythematosus presenting as Stevens-Johnson syndrome]. ( Bellakhal, S; Ben Kaab, B; Derbel, F; Douggui, MH; Souissi, A; Teyeb, Z, 2015) |
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel." | 1.40 | Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014) |
"Cbz at a dosage of 25mg/m(2) intravenously every 3 wk combined with 5mg of oral prednisone twice a day." | 1.39 | Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. ( Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013) |
"Two patients were presenting non-Hodgkin lymphoma, one had Hodgkin's disease, one had chronic myeloid leukaemia in progression and one had an undifferentiated lymphomatous process." | 1.38 | [Acquired ichthyosis and haematological malignancies: five cases]. ( Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ, 2012) |
"In 40 to 50% of DBA patients, congenital abnormalities mostly in the cephalic area and in thumbs and upper limbs have been described." | 1.36 | Diamond-Blackfan anemia, ribosome and erythropoiesis. ( Da Costa, L; Leblanc, T; Mohandas, N; Moniz, H; Simansour, M; Tchernia, G, 2010) |
"Cutaneous eruptive xanthomas are characteristics lesions of hyperlipidemia." | 1.36 | Eruptive neutrophilic xanthomas. ( Aldabagh, B; Bergfeld, W, 2010) |
"However IFNalpha-induced systemic lupus erythematosus is a rare event." | 1.36 | Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. ( Galicier, L; Glotz, D; Peraldi, MN; Pillebout, E; Ripault, MP; Touzot, F; Touzot, M, 2010) |
"Sneddon-Wilkinson disease or subcorneal pustular dermatosis (SPD) is a rare, benign inflammatory skin disorder of unknown etiology." | 1.35 | Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. ( Newman, J; Ratnarathorn, M, 2008) |
"Retroperitoneal fibrosis is an often idiopathic disease that can cause compression of retroperitoneal structures such as the ureters." | 1.34 | [Fatigue, loss of appetite and anuria due to retroperitoneal fibrosis]. ( de Beus, E; Rensma, PL, 2007) |
"The prednisone dose was reduced by a mean of 25% in these same 13 patients." | 1.31 | Experiences with leflunomide in solid organ transplantation. ( Brady, L; Chong, A; Huang, W; Jensik, S; Kottayil, A; Longstreth, J; Millis, M; Mital, D; Williams, JW, 2002) |
"The National Comprehensive Cancer Network (NCCN) of cancer centers has recommended that all patients aged 70 years and older treated with CHOP or cytotoxic chemotherapy of comparable intensity should receive prophylactic G-CSF administration, and that the hemoglobin concentration be maintained at >or=12 g/dl in elderly patients undergoing chemotherapy." | 1.31 | Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. ( Bokemeyer, C; Honecker, F; Kolb, G; Lipp, HP; Späth-Schwalbe, E; Wedding, U, 2002) |
"We describe a patient with quiet systemic lupus erythematosus who developed a hypereosinophilic syndrome." | 1.30 | Hypereosinophilic syndrome presenting with diarrhoea and anaemia in a patient with systemic lupus erythematosus. ( Beerman, H; Markusse, HM; Schravenhoff, R, 1998) |
"A kidney biopsy was consistent with Wegener's granulomatosis, and treatment with prednisone and cyclophosphamide was associated with normalization of serum calcium levels, improved renal function, a marked decrease in serum 1,25(OH)2D levels, and increased serum intact parathyroid hormone levels." | 1.29 | Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. ( Findling, JW; Redlin, KC; Shaker, JL; Warren, GV, 1994) |
"In three patients with advanced Hodgkin's disease treated with combination chemotherapy (MOPP) incorporating vincristine, and receiving at the same time a fixed daily dose of 8000 U of rHu-EPO subcutaneously for 10 to 15 days because of myelosuppressive anemia, myeloaspirates were performed one week before and 24 hours after the administration of vincristine." | 1.28 | Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia. ( Marmont, AM, 1992) |
"93 children and adolescents with Crohn's disease have been studied." | 1.27 | [Crohn's disease in children and adolescents]. ( Bensoussan, A; Chouraqui, JP; Le Luyer, B; Morin, CL; Roy, CC; Weber, A, 1985) |
"Anemia and leukopenia have been reported in sarcoidosis." | 1.27 | The anemia of sarcoidosis. ( Baughman, RP; Lower, EE; Martelo, OJ; Smith, JT, 1988) |
"The patient died of respiratory failure because of infiltration of the lungs by malignant histiocytes." | 1.25 | Acute lymphoblastic leukemia terminating as histiocytic medullary reticulosis. ( Shreiner, DP, 1975) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 153 (60.47) | 18.7374 |
1990's | 14 (5.53) | 18.2507 |
2000's | 35 (13.83) | 29.6817 |
2010's | 46 (18.18) | 24.3611 |
2020's | 5 (1.98) | 2.80 |
Authors | Studies |
---|---|
Havlichek, D | 1 |
Choung, RS | 1 |
Murray, JA | 1 |
Qu, S | 2 |
Xu, Z | 2 |
Qin, T | 2 |
Li, B | 2 |
Pan, L | 2 |
Chen, J | 1 |
Yan, X | 1 |
Wu, J | 1 |
Zhang, Y | 3 |
Zhang, P | 1 |
Gale, RP | 3 |
Xiao, Z | 2 |
Tryfon, S | 1 |
Papadopoulou, E | 1 |
Psarros, G | 1 |
Agrafiotis, M | 1 |
Saroglou, M | 1 |
Chen, G | 2 |
Wu, D | 1 |
Li, MX | 1 |
Okello, CD | 1 |
Omoding, A | 1 |
Ddungu, H | 1 |
Mulumba, Y | 1 |
Orem, J | 1 |
Maeda, Y | 1 |
Nishimori, H | 1 |
Yoshida, I | 1 |
Hiramatsu, Y | 1 |
Uno, M | 1 |
Masaki, Y | 1 |
Sunami, K | 1 |
Masunari, T | 1 |
Nawa, Y | 1 |
Yamane, H | 1 |
Gomyo, H | 1 |
Takahashi, T | 1 |
Yano, T | 1 |
Matsuo, K | 1 |
Ohshima, K | 1 |
Nakamura, S | 1 |
Yoshino, T | 1 |
Tanimoto, M | 1 |
Nakayama, S | 1 |
Matsuda, M | 1 |
Adachi, T | 1 |
Sueda, S | 1 |
Ohashi, Y | 1 |
Awaji, S | 1 |
Hashimoto, S | 1 |
Matsumura, I | 1 |
Saito, T | 1 |
Okamura, A | 1 |
Inoue, J | 1 |
Makiura, D | 1 |
Doi, H | 1 |
Yakushijin, K | 1 |
Matsuoka, H | 1 |
Sakai, Y | 1 |
Ono, R | 1 |
Quintanilla-González, L | 1 |
Torres-Villalobos, G | 1 |
Hinojosa-Azaola, A | 1 |
Komrokji, RS | 1 |
Al Ali, NH | 1 |
Padron, E | 1 |
Cogle, C | 1 |
Tinsley, S | 1 |
Sallman, D | 1 |
Lancet, JE | 1 |
Lis, AF | 1 |
Ge, YL | 1 |
Liu, CH | 1 |
Zhang, Q | 1 |
Wang, YM | 1 |
Wang, N | 1 |
Zhang, HF | 1 |
Chen, QC | 1 |
Chen, Y | 1 |
Li, WQ | 1 |
Zhu, XY | 1 |
Fu, AS | 1 |
Puente, J | 1 |
González-Del-Alba, A | 1 |
Sala-Gonzalez, N | 1 |
Méndez-Vidal, MJ | 1 |
Pinto, A | 1 |
Rodríguez, Á | 1 |
Cuevas Sanz, JM | 1 |
Muñoz Del Toro, JR | 1 |
Useros Rodríguez, E | 1 |
García García-Porrero, Á | 1 |
Vázquez, S | 1 |
Hou, S | 1 |
Hegerova, LT | 1 |
Lin, Y | 1 |
Papadopoulou, V | 1 |
Ioannou, S | 1 |
Levidou, G | 1 |
Variami, E | 1 |
Kouzis, P | 1 |
Siakantaris, M | 1 |
Michaelson, MD | 1 |
Oudard, S | 1 |
Ou, YC | 1 |
Sengeløv, L | 1 |
Saad, F | 1 |
Houede, N | 1 |
Ostler, P | 1 |
Stenzl, A | 1 |
Daugaard, G | 1 |
Jones, R | 1 |
Laestadius, F | 1 |
Ullèn, A | 1 |
Bahl, A | 1 |
Castellano, D | 1 |
Gschwend, J | 2 |
Maurina, T | 1 |
Chow Maneval, E | 1 |
Wang, SL | 1 |
Lechuga, MJ | 1 |
Paolini, J | 1 |
Chen, I | 1 |
Ruan, J | 1 |
Gregory, SA | 1 |
Christos, P | 1 |
Martin, P | 1 |
Furman, RR | 1 |
Coleman, M | 1 |
Leonard, JP | 1 |
Heidenreich, A | 2 |
Bracarda, S | 1 |
Mason, M | 1 |
Ozen, H | 1 |
Sengelov, L | 1 |
Van Oort, I | 1 |
Papandreou, C | 1 |
Fossa, S | 1 |
Hitier, S | 1 |
Climent, MA | 1 |
Tefferi, A | 4 |
Hudgens, S | 1 |
Mesa, R | 1 |
Verstovsek, S | 4 |
Passamonti, F | 2 |
Cervantes, F | 4 |
Rivera, C | 1 |
Tencer, T | 1 |
Khan, ZM | 1 |
Cheng, J | 1 |
Talamo, G | 1 |
Malysz, J | 1 |
Ochmann, M | 1 |
Lamy, T | 1 |
Loughran, TP | 1 |
Daver, N | 1 |
Shastri, A | 1 |
Kadia, T | 1 |
Newberry, K | 1 |
Pemmaraju, N | 1 |
Jabbour, E | 1 |
Zhou, L | 1 |
Pierce, S | 1 |
Cortes, J | 2 |
Kantarjian, H | 1 |
Xu, J | 1 |
Fang, L | 1 |
Zhang, H | 1 |
Hu, N | 1 |
Watson, P | 1 |
Brennan, A | 1 |
Birch, H | 1 |
Fang, H | 1 |
Petri, M | 1 |
Hong, J | 1 |
Woo, HS | 1 |
Kim, H | 1 |
Ahn, HK | 1 |
Sym, SJ | 1 |
Park, J | 1 |
Ahn, JY | 1 |
Cho, EK | 1 |
Shin, DB | 1 |
Lee, JH | 2 |
Hernández-Boluda, JC | 1 |
Martínez-Trillos, A | 1 |
García-Gutiérrez, V | 1 |
Ferrer-Marín, F | 1 |
Xicoy, B | 1 |
Alvarez-Larrán, A | 1 |
Kerguelen, A | 1 |
Barba, P | 1 |
Gómez, M | 1 |
Herrera, JC | 1 |
Correa, JG | 1 |
Bellakhal, S | 1 |
Ben Kaab, B | 1 |
Teyeb, Z | 1 |
Souissi, A | 1 |
Derbel, F | 1 |
Douggui, MH | 1 |
Adams, HJ | 1 |
de Klerk, JM | 1 |
Fijnheer, R | 1 |
Heggelman, BG | 1 |
Dubois, SV | 1 |
Nievelstein, RA | 1 |
Kwee, TC | 1 |
Adam, Z | 1 |
Pour, L | 1 |
Krejčí, M | 1 |
Ševčíková, S | 1 |
Pourová, E | 1 |
Ševčíková, E | 1 |
Král, Z | 1 |
Mayer, J | 1 |
Lakkaraja, M | 1 |
Jin, JC | 1 |
Manotas, KC | 1 |
Vinograd, CA | 1 |
Ferd, P | 1 |
Gabor, J | 1 |
Wissert, M | 1 |
Berkowitz, RL | 1 |
McFarland, JG | 1 |
Bussel, JB | 1 |
Charpentier, AM | 1 |
Friedman, DL | 1 |
Wolden, S | 1 |
Schwartz, C | 1 |
Gill, B | 1 |
Sykes, J | 1 |
Albert-Green, A | 1 |
Kelly, KM | 1 |
Constine, LS | 1 |
Hodgson, DC | 1 |
Popp, A | 1 |
Jurcuţ, C | 1 |
Balaban, DV | 1 |
Șotcan, M | 1 |
Laurila, K | 1 |
Jinga, M | 1 |
Xie, Y | 1 |
Guo, JQ | 1 |
Hua, Y | 1 |
Zhao, WH | 1 |
Sun, Q | 1 |
Lu, XT | 1 |
Lu, J | 1 |
Huang, SY | 1 |
Qiu, L | 1 |
Lee, JJ | 1 |
Liu, T | 1 |
Yoon, SS | 1 |
Kim, K | 1 |
Shen, ZX | 1 |
Eom, HS | 1 |
Chen, WM | 1 |
Min, CK | 1 |
Kim, HJ | 1 |
Lee, JO | 1 |
Kwak, JY | 1 |
Yiu, W | 1 |
Ervin-Haynes, A | 1 |
Hulin, C | 1 |
Facon, T | 1 |
Ratnarathorn, M | 1 |
Newman, J | 1 |
Santoro, RC | 1 |
Prejanò, S | 1 |
Barosi, G | 1 |
Roboz, GJ | 1 |
Gisslinger, H | 1 |
Paquette, RL | 1 |
Rivera, CE | 1 |
Deeg, HJ | 1 |
Thiele, J | 1 |
Kvasnicka, HM | 1 |
Vardiman, JW | 1 |
Bekele, BN | 1 |
Mesa, RA | 2 |
Kantarjian, HM | 2 |
Quintás-Cardama, A | 1 |
Manshouri, T | 1 |
Thomas, D | 1 |
Ravandi, F | 1 |
Garcia-Manero, G | 1 |
Ferrajoli, A | 1 |
Bueso-Ramos, C | 1 |
Sternberg, CN | 1 |
Petrylak, DP | 1 |
Sartor, O | 1 |
Witjes, JA | 1 |
Demkow, T | 1 |
Ferrero, JM | 1 |
Eymard, JC | 1 |
Falcon, S | 1 |
Calabrò, F | 1 |
James, N | 1 |
Bodrogi, I | 1 |
Harper, P | 1 |
Wirth, M | 2 |
Berry, W | 1 |
Petrone, ME | 1 |
McKearn, TJ | 1 |
Noursalehi, M | 1 |
George, M | 1 |
Rozencweig, M | 1 |
Malyszko, J | 1 |
Malyszko, JS | 1 |
Mysliwiec, M | 1 |
Jöbsis, JJ | 1 |
Fijnvandraat, K | 1 |
Stapel, SO | 1 |
Bouts, AH | 1 |
Touzot, M | 1 |
Touzot, F | 1 |
Galicier, L | 1 |
Ripault, MP | 1 |
Peraldi, MN | 1 |
Glotz, D | 1 |
Pillebout, E | 1 |
Engert, A | 3 |
Josting, A | 2 |
Haverkamp, H | 1 |
Villalobos, M | 1 |
Lohri, A | 1 |
Sökler, M | 1 |
Zijlstra, J | 1 |
Sturm, I | 1 |
Topp, MS | 1 |
Rank, A | 1 |
Zenz, T | 1 |
Vogelhuber, M | 1 |
Nogova, L | 1 |
Borchmann, P | 1 |
Fuchs, M | 1 |
Flechtner, HH | 1 |
Diehl, V | 2 |
Aldabagh, B | 1 |
Bergfeld, W | 1 |
Bauer, K | 1 |
Herbst, C | 1 |
Brillant, C | 1 |
Monsef, I | 1 |
Kluge, S | 1 |
Skoetz, N | 1 |
Da Costa, L | 1 |
Moniz, H | 1 |
Simansour, M | 1 |
Tchernia, G | 1 |
Mohandas, N | 1 |
Leblanc, T | 1 |
El Halim Mohamed Abu Hamar, A | 1 |
Mansour, S | 1 |
El Shebiney, M | 1 |
El Bary, NM | 1 |
Sadaka, E | 1 |
Maria, A | 1 |
Gerecitano, J | 1 |
Portlock, C | 1 |
Hamlin, P | 1 |
Moskowitz, CH | 1 |
Noy, A | 1 |
Straus, D | 1 |
Schulman, P | 1 |
Dumitrescu, O | 1 |
Sarasohn, D | 1 |
Pappanicholaou, J | 1 |
Iasonos, A | 1 |
Zhang, Z | 1 |
Mo, Q | 1 |
Horanlli, E | 1 |
Rojas, CN | 1 |
Zelenetz, AD | 1 |
O'Connor, OA | 1 |
Merli, F | 2 |
Luminari, S | 2 |
Rossi, G | 1 |
Mammi, C | 2 |
Marcheselli, L | 2 |
Tucci, A | 1 |
Ilariucci, F | 1 |
Chiappella, A | 1 |
Musso, M | 1 |
Di Rocco, A | 1 |
Stelitano, C | 3 |
Alvarez, I | 1 |
Baldini, L | 3 |
Mazza, P | 1 |
Salvi, F | 1 |
Arcari, A | 1 |
Fragasso, A | 1 |
Gobbi, PG | 2 |
Liberati, AM | 1 |
Federico, M | 2 |
Morabito, F | 1 |
Hohaus, S | 1 |
Gentile, M | 1 |
Montanini, A | 1 |
La Sala, A | 1 |
Scalone, R | 1 |
Voso, MT | 1 |
Iannitto, E | 1 |
Gobbi, P | 1 |
Berrady, R | 1 |
Baybay, H | 1 |
Khammar, Z | 1 |
Lahlou, M | 1 |
Lamchachti, L | 1 |
Gallouj, S | 1 |
El Hatimi, A | 1 |
Mernissi, FZ | 1 |
Bono, W | 1 |
Pönisch, W | 1 |
Andrea, M | 1 |
Wagner, I | 1 |
Hammerschmidt, D | 1 |
Kreibich, U | 1 |
Schwarzer, A | 1 |
Zehrfeld, T | 1 |
Schwarz, M | 1 |
Winkelmann, C | 1 |
Petros, S | 1 |
Bachmann, A | 1 |
Lindner, T | 1 |
Niederwieser, D | 1 |
Spina, M | 1 |
Balzarotti, M | 1 |
Uziel, L | 1 |
Ferreri, AJ | 1 |
Fratino, L | 1 |
Magagnoli, M | 1 |
Talamini, R | 1 |
Giacalone, A | 1 |
Ravaioli, E | 1 |
Chimienti, E | 1 |
Berretta, M | 1 |
Lleshi, A | 1 |
Santoro, A | 1 |
Tirelli, U | 1 |
Nassiri, M | 1 |
Robertson, MJ | 1 |
Hertzberg, L | 1 |
Czader, MB | 1 |
Scholz, HJ | 1 |
Rogenhofer, S | 1 |
Arsov, C | 1 |
Retz, M | 1 |
Müller, SC | 1 |
Albers, P | 1 |
Steiner, U | 1 |
Miller, K | 1 |
Heinrich, E | 1 |
Trojan, L | 1 |
Volkmer, B | 1 |
Honecker, F | 2 |
Bokemeyer, C | 2 |
Keck, B | 1 |
Otremba, B | 1 |
Ecstein-Fraisse, E | 1 |
Pfister, D | 1 |
Rapp, M | 2 |
Berg, C | 1 |
Knoepfle, G | 1 |
Müller, AM | 2 |
Bartmann, P | 1 |
Iriyama, N | 1 |
Takahashi, H | 1 |
Hatta, Y | 1 |
Miura, K | 1 |
Kobayashi, Y | 1 |
Kurita, D | 1 |
Hirabayashi, Y | 1 |
Hojo, A | 1 |
Kodaira, H | 1 |
Yagi, M | 1 |
Kiso, S | 1 |
Uchino, Y | 1 |
Nakagawa, M | 1 |
Kusuda, M | 1 |
Kobayashi, S | 1 |
Horikoshi, A | 1 |
Kura, Y | 1 |
Yamazaki, T | 1 |
Sawada, U | 1 |
Takeuchi, J | 1 |
Morrow, TJ | 1 |
Volpe, S | 1 |
Gupta, S | 1 |
Tannous, RE | 1 |
Fridman, M | 1 |
Steensma, DP | 1 |
Pardanani, A | 1 |
Li, CY | 1 |
Elliott, M | 1 |
Kaufmann, SH | 1 |
Wiseman, G | 1 |
Gray, LA | 1 |
Schroeder, G | 1 |
Reeder, T | 1 |
Zeldis, JB | 1 |
Cavallo, R | 1 |
Merlino, C | 1 |
Re, D | 1 |
Bollero, C | 1 |
Bergallo, M | 1 |
Lembo, D | 1 |
Musso, T | 1 |
Leonardi, G | 1 |
Segoloni, GP | 1 |
Ponzi, AN | 1 |
Sieber, M | 1 |
Bredenfeld, H | 1 |
Reineke, T | 1 |
Rueffer, U | 1 |
Koch, T | 1 |
Naumann, R | 1 |
Boissevain, F | 1 |
Koch, P | 1 |
Worst, P | 1 |
Soekler, M | 1 |
Eich, H | 1 |
Müller-Hermelink, HK | 1 |
Franklin, J | 1 |
Paulus, U | 1 |
Wolf, J | 1 |
Meier, P | 1 |
Gilabert, C | 1 |
Burnier, M | 1 |
Blanc, E | 1 |
Malliti, M | 1 |
Junot, H | 1 |
Fievet, MH | 1 |
Gabarre, J | 1 |
Taright, N | 1 |
Vernant, JP | 1 |
Thuillier, A | 1 |
SUSSMAN, LN | 1 |
DORDICK, JR | 1 |
POLLI, E | 1 |
CROSTI, PF | 1 |
CARRARA, PM | 1 |
STEFANINI, M | 1 |
MARTINO, NB | 1 |
REMY, D | 1 |
BROCKHAUS, L | 1 |
LICHTMAN, HC | 1 |
RABINER, SF | 1 |
SHIELDS, GS | 1 |
PLOTKIN, N | 1 |
LEVERE, R | 1 |
GARRAHAN, JP | 2 |
ALBORES, JM | 1 |
SENET, RE | 1 |
CEDRATO, AE | 1 |
CANTONI, L | 1 |
CICONALI, M | 1 |
SCALTRINI, GC | 1 |
VOLTA, A | 1 |
SAXENA, KM | 1 |
SARASWAT, KD | 1 |
BRUZZESE, L | 1 |
IULIANI, G | 1 |
ROGER, S | 1 |
FROST, JW | 1 |
GOLDWEIN, MI | 1 |
PITNEY, WR | 1 |
O'SULLIVAN, WJ | 1 |
OWEN, JA | 1 |
PARRY, EH | 1 |
KILPATRICK, GS | 1 |
HARDISTY, RM | 1 |
OSTERGAARD KRISTENSEN, HP | 4 |
FRIIS, T | 4 |
JEUNE, M | 1 |
GERMAIN, D | 1 |
HUMBERT, G | 1 |
NIVELON, JL | 1 |
CROLLE, G | 1 |
COSCIA, GC | 1 |
BASSO, F | 1 |
SEIP, M | 1 |
KURTIDES, ES | 1 |
ALT, HL | 1 |
LETMAN, H | 1 |
JANDL, JH | 1 |
RITZ, ND | 2 |
HABER, A | 1 |
WEINER, AA | 1 |
IMERSLUND, O | 1 |
BJORNSTAD, P | 1 |
BRUS, I | 1 |
PARANDE, AS | 1 |
JAIN, KL | 1 |
RANLOV, P | 1 |
VIDEBAEK, A | 1 |
EMPARANZA, E | 1 |
HASBUN, SJ | 1 |
VILDOSOLA, J | 1 |
OLCESE, A | 1 |
FAIGEL, HC | 1 |
KUHN, E | 1 |
KOHN, R | 1 |
CHAKRABARTI, R | 1 |
FEARNLEY, GR | 1 |
HOCKING, ED | 1 |
ROSNER, F | 3 |
SUSSMAN, SN | 1 |
GALLINELLI, R | 1 |
TRALDI, A | 1 |
KEHOE, EL | 1 |
NEWCOMER, KL | 1 |
FARRERASVALENTI, P | 1 |
ROZMAN, C | 2 |
WOESSNER, S | 1 |
MYKHAMEDZIANOVA, GS | 1 |
MASSIMO, L | 2 |
RAINERO, L | 1 |
MELVIN, KE | 1 |
DAVIDSON, JN | 1 |
BURNINGHAM, RA | 1 |
RESTREPO, A | 1 |
PUGH, RP | 1 |
BROWN, EB | 1 |
SCHLOSSMAN, SF | 1 |
KHURI, PD | 1 |
LESSNER, HE | 1 |
HARRINGTON, WJ | 1 |
SZEKELY, K | 1 |
LABRAM, C | 1 |
JACOTTET, M | 1 |
ELEFANT, E | 1 |
JEKLEROVA, J | 1 |
JANELE, J | 1 |
DUHAMEL, G | 1 |
MARCHAL, G | 1 |
MILLS, SD | 1 |
KYLE, RA | 3 |
HALLENBECK, GA | 1 |
PEASE, GL | 1 |
CREE, IC | 1 |
HOLLEY, HL | 1 |
HOGAN, RS | 1 |
BARTOLOZZI, G | 1 |
PAVARI, E | 1 |
GUAZZELLI, C | 1 |
MARIANELLI, L | 1 |
O'LEARY, JA | 1 |
BODIAN, M | 1 |
SHELDON, W | 1 |
LIGHTWOOD, R | 1 |
ISRAELS, LG | 1 |
ERSLEV, AJ | 1 |
GROSS, S | 1 |
NEWMAN, AJ | 1 |
PECORELLA, F | 1 |
AZEN, EA | 1 |
CLATANOFF, DV | 1 |
EBIHARA, T | 1 |
ISHIKAWA, A | 1 |
YAMBE, D | 1 |
WOODLIFF, HJ | 1 |
KAKULAS, BA | 1 |
BELLOT, SM | 1 |
ROSS, JD | 1 |
ROSENBAUM, E | 1 |
KEENEY, EL | 1 |
ROSSI, V | 1 |
BIANCHINI, E | 1 |
MAINWARING, D | 1 |
KEIDAN, SE | 1 |
KOZINN, PJ | 1 |
MOSS, AH | 1 |
KAUFMAN, A | 1 |
MCANDREW, GM | 1 |
BETKE, K | 1 |
HEINE, KM | 1 |
HERRMANN, H | 1 |
STOBBE, H | 1 |
KENNEDY, BJ | 1 |
DUNEA, G | 1 |
NAKAMOTO, S | 1 |
STRAFFON, RA | 1 |
FIGUEROA, JE | 1 |
VERSACI, AA | 1 |
SHIBAGAKI, M | 1 |
KOLFF, WJ | 1 |
RETIEF, FP | 1 |
WASSERMANN, HP | 1 |
HOFMEYER, NG | 1 |
ROSNER, P | 1 |
HAUSSER, E | 1 |
RUHRMANN, G | 1 |
BEAL, RW | 1 |
KRONENBERG, H | 1 |
FIRKIN, BG | 1 |
HERSKO, C | 1 |
IZAK, G | 1 |
GOLDSTEIN, C | 1 |
PECHET, L | 1 |
MACLACHLAN, MJ | 1 |
RODNAN, GP | 1 |
COOPER, WM | 1 |
FENNELL, RH | 1 |
EDWARDS, CL | 1 |
GENGOZIAN, N | 1 |
LUEBECK, I | 1 |
SUCKOW, KL | 1 |
HEINE, K | 1 |
GRUENWALD, H | 1 |
TAUB, RN | 1 |
WONG, FM | 1 |
KIOSSOBLOU, KA | 1 |
DAMESHEK, W | 1 |
MEHRA, SK | 1 |
DAVIES, DM | 1 |
BELL, SM | 1 |
LOGE, JP | 1 |
DOBBS, CE | 1 |
HUCZEK-GLEBOCKI, J | 1 |
OSTERCZY, Z | 1 |
LINSK, JA | 1 |
MURRAY, CK | 1 |
MOODY, EA | 1 |
MOVITT, ER | 1 |
MANGUM, JF | 1 |
JUNG, ED | 1 |
PORTER, WR | 1 |
Owais, Z | 1 |
Dane, J | 1 |
Cumming, CG | 1 |
Basi, S | 1 |
Schulman, G | 1 |
Fogo, AB | 1 |
Callan, MB | 1 |
Preziosi, D | 1 |
Mauldin, E | 1 |
Pan, ZH | 1 |
Huang, HQ | 1 |
Lin, XB | 1 |
Xia, YF | 1 |
Xia, ZJ | 1 |
Peng, YL | 1 |
Cai, QQ | 1 |
Lin, TY | 1 |
Jiang, WQ | 1 |
Guan, ZZ | 1 |
Johnston, KL | 1 |
Farnen, JP | 1 |
Manske, BR | 1 |
Go, RS | 1 |
Cheung, PP | 1 |
Richards, G | 1 |
de Beus, E | 1 |
Rensma, PL | 1 |
Vilá, LM | 1 |
Molina, MJ | 1 |
Scheinfeld, N | 1 |
Schecter, JM | 1 |
Mears, JG | 1 |
Alobeid, B | 1 |
Gaglio, PJ | 1 |
Doganis, D | 1 |
Baka, M | 1 |
Pourtsidis, A | 1 |
Bouhoutsou, D | 1 |
Varvoutsi, M | 1 |
Stamos, G | 1 |
Anastasiou, N | 1 |
Androulakakis, E | 1 |
Vasilatou-Kosmidis, H | 1 |
Errante, D | 1 |
Bianco, A | 1 |
Aversa, SML | 1 |
Salvagno, L | 1 |
Garay, G | 1 |
Milone, J | 1 |
Dibar, E | 1 |
Pavlovsky, S | 1 |
Kvicala, R | 1 |
Sackmann Muriel, F | 1 |
Montres Varela, D | 1 |
Eppinger-Helft, M | 1 |
Alfinito, F | 1 |
Formisano, S | 1 |
Rotoli, B | 1 |
Belisario, A | 1 |
D'Antuono, G | 1 |
Modiano, A | 1 |
Pascual, JF | 1 |
Molina, M | 1 |
Lopez, J | 1 |
Barista, I | 1 |
Tekuzman, G | 1 |
Firat, D | 1 |
Baltali, E | 1 |
Kansu, E | 1 |
Kars, A | 1 |
Ozisik, Y | 1 |
Ruacan, S | 1 |
Uzunalimoğlu, B | 1 |
Karaağaoğlu, E | 1 |
Weiss, LM | 1 |
Gonzalez, E | 1 |
Miller, SB | 1 |
Agudelo, CA | 1 |
Witzig, TE | 1 |
Weitz, JJ | 1 |
Lundberg, JH | 1 |
Shaker, JL | 1 |
Redlin, KC | 1 |
Warren, GV | 1 |
Findling, JW | 1 |
Moltyaner, Y | 1 |
Tenenbaum, J | 1 |
Zlatanic, J | 1 |
Korelitz, BI | 1 |
Wisch, N | 1 |
Kim, P | 1 |
Ammirati, M | 1 |
Schwarz, S | 1 |
Gruenstein, S | 1 |
Lipsey, L | 1 |
Markusse, HM | 1 |
Schravenhoff, R | 1 |
Beerman, H | 1 |
Kettaneh, A | 1 |
Hayem, G | 1 |
Palazzo, E | 1 |
Debandt, M | 1 |
Lebail-Darné, JL | 1 |
Roux, S | 1 |
Kahn, MF | 1 |
Meyer, O | 1 |
Witzens, M | 1 |
Egerer, G | 1 |
Stahl, D | 1 |
Werle, E | 1 |
Goldschmidt, H | 1 |
Haas, R | 1 |
Hamasaki, A | 1 |
Ishii, K | 1 |
Yamaguchi, K | 1 |
Sunamoto, M | 1 |
Ozaki, H | 1 |
Yanagita, M | 1 |
Wakatsuki, Y | 1 |
Horiuchi, H | 1 |
Nakahata, Y | 1 |
Kita, T | 1 |
San Miguel, JF | 1 |
Bladé Creixenti, J | 1 |
García-Sanz, R | 1 |
Heilborn, JD | 1 |
Ståhle-Bäckdahl, M | 1 |
Albertioni, F | 1 |
Vassilaki, I | 1 |
Peterson, C | 1 |
Stephansson, E | 1 |
Bueno, J | 2 |
Zuazu, J | 1 |
Villalba, T | 1 |
Julià, A | 1 |
Ghirardelli, ML | 1 |
Avanzini, P | 1 |
Quarta, G | 1 |
Broglia, C | 1 |
Loni, C | 1 |
Silingardi, V | 1 |
Ascari, E | 2 |
Hoyt, PG | 1 |
Gill, MS | 1 |
Angel, KL | 1 |
Gaunt, SD | 1 |
Dial, SM | 1 |
Landreneau, RM | 1 |
Messick, JB | 1 |
Berent, LM | 1 |
Ehrhart, EJ | 1 |
Wasmer, CC | 1 |
Emre, S | 1 |
Bilge, I | 1 |
Sirin, A | 1 |
Kilicaslan, I | 1 |
Nayir, A | 1 |
Oktem, F | 1 |
Uysal, V | 1 |
Colombi, M | 1 |
Guffanti, A | 1 |
Alietti, A | 1 |
Latargia, ML | 1 |
Vener, C | 1 |
Maiolo, AT | 1 |
Niitsu, N | 1 |
Iijima, K | 1 |
Williams, JW | 1 |
Mital, D | 1 |
Chong, A | 1 |
Kottayil, A | 1 |
Millis, M | 1 |
Longstreth, J | 1 |
Huang, W | 1 |
Brady, L | 1 |
Jensik, S | 1 |
Wedding, U | 1 |
Späth-Schwalbe, E | 1 |
Lipp, HP | 1 |
Kolb, G | 1 |
Vivancos, J | 1 |
Vila, M | 1 |
Serra, A | 1 |
Loscos, J | 1 |
Anguita, A | 1 |
Rea, TH | 1 |
Ben Taarit, C | 1 |
Turki, S | 1 |
Ben Maïz, H | 1 |
Cotter, SM | 1 |
Wechsler, HL | 1 |
Stavrides, A | 1 |
Sawitsky, A | 1 |
Rai, KR | 1 |
Glidewell, O | 1 |
Silver, RT | 2 |
Newton, PA | 1 |
Shreiner, DP | 1 |
Alexanian, R | 1 |
Balcerzak, S | 1 |
Bonnet, JD | 2 |
Gehan, EA | 2 |
Haut, A | 1 |
Hewlett, JS | 2 |
Monto, RW | 1 |
Silverstein, MN | 2 |
Ghose, MK | 1 |
Shensa, S | 1 |
Lerner, PI | 1 |
Marmont, AM | 1 |
Schiller, JH | 1 |
Hawkins, MJ | 1 |
O'Connell, MJ | 1 |
Sielaff, K | 1 |
Borden, EC | 1 |
López-Guillermo, A | 1 |
Ribera, JM | 1 |
Feliu, E | 1 |
Florensa, L | 1 |
Le Luyer, B | 1 |
Morin, CL | 1 |
Roy, CC | 1 |
Weber, A | 1 |
Chouraqui, JP | 1 |
Bensoussan, A | 1 |
Tejani, A | 1 |
Butt, KM | 1 |
Khawar, MR | 1 |
Hong, JH | 1 |
Fusi, M | 1 |
Pomrantz, A | 1 |
Lower, EE | 1 |
Smith, JT | 1 |
Martelo, OJ | 1 |
Baughman, RP | 2 |
Montserrat, E | 1 |
Alcalá, A | 1 |
Parody, R | 1 |
Domingo, A | 1 |
García-Conde, J | 1 |
Ferrán, C | 1 |
Sanz, MA | 1 |
Giralt, M | 1 |
Rubio, D | 1 |
Balaban, EP | 1 |
Buchanan, GR | 1 |
Graham, M | 1 |
Frenkel, EP | 1 |
Dewulf, E | 1 |
Vielle, G | 1 |
Hongque, MP | 1 |
Arianoff, AA | 1 |
Connor, B | 1 |
Warrell, DA | 1 |
Davidson, NM | 1 |
Omerod, LD | 1 |
Pope, HM | 1 |
Watkins, BJ | 1 |
Greenwood, BM | 1 |
Ried, HA | 1 |
Schubert, JC | 1 |
Martin, H | 1 |
Biggs, JC | 1 |
Adam, JE | 1 |
Vivien, P | 1 |
Gastard, J | 1 |
Allannic, H | 1 |
Morel, H | 1 |
Loussouarn, J | 1 |
Foley, HT | 1 |
Bennett, JM | 1 |
Carbone, PP | 1 |
Hoogstraten, B | 1 |
Ansell, BM | 1 |
Bywaters, EG | 1 |
Bodey, GP | 1 |
Coltman, CA | 1 |
Freireich, EJ | 1 |
Haut, AB | 1 |
McCredit, KB | 1 |
Saiki, JH | 1 |
Wilson, HE | 1 |
Fairley, GH | 1 |
Robertson, JH | 1 |
Crozier, EH | 1 |
Hollinger, M | 1 |
Burton, JL | 1 |
Greaves, MW | 1 |
Perugini, S | 1 |
Fontana, G | 1 |
Murphy, GP | 1 |
Mirand, EA | 1 |
Grace, JT | 1 |
Fine, RN | 1 |
Korsch, BM | 1 |
Stiles, Q | 1 |
Riddell, H | 1 |
Edelbrock, HH | 1 |
Brennan, LP | 1 |
Grushkin, CM | 1 |
Lieberman, E | 1 |
Greenberg, LH | 1 |
Wong, S | 1 |
Richardson, AP | 1 |
Dollinger, MR | 1 |
Honetz, N | 1 |
Krasilnikoff, PA | 1 |
Lee, SL | 2 |
Kaufmann, RW | 1 |
Schechter, GP | 1 |
McFarland, W | 1 |
Dyrkorn, K | 1 |
Magnus, EM | 1 |
Siering, H | 1 |
Eitner, K | 1 |
Aasved, H | 1 |
Jones, FL | 1 |
Blodgett, RC | 1 |
Ruberman, W | 1 |
Glasberg, S | 1 |
Johnston, DH | 1 |
Duverne, J | 1 |
Volle, H | 1 |
Demilly, J | 1 |
Mantout, B | 1 |
Szreder, W | 1 |
Mitus, WJ | 1 |
Coleman, N | 1 |
Kiossoglou, KA | 1 |
Waaler, G | 1 |
Lévèque, B | 1 |
Debauchez, C | 1 |
Deflandre, L | 1 |
Marie, J | 1 |
Krupa, B | 1 |
Muszkowska-Penson, J | 1 |
Rynkiewicz, H | 1 |
Horoszek, S | 1 |
Arndt, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185] | Phase 2 | 36 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2018-11-07 | Active, not recruiting | ||
An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA[NCT00106418] | Phase 2 | 35 participants (Actual) | Interventional | 2003-05-07 | Completed | ||
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650] | Phase 3 | 873 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.) | ||
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325] | Phase 2 | 127 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)[NCT00946270] | Phase 2 | 70 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia[NCT00194987] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936] | Phase 3 | 1,623 participants (Actual) | Interventional | 2008-08-21 | Completed | ||
A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915] | Phase 1 | 3 participants (Actual) | Interventional | 2019-01-12 | Terminated (stopped due to Company decision) | ||
Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)[NCT00352794] | Phase 2 | 40 participants (Actual) | Interventional | 2006-07-07 | Completed | ||
Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia[NCT01464164] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2012-01-31 | Terminated (stopped due to Supporter terminated the study due to no active patients (secondary to travel restrictions due to COVID).) | ||
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)[NCT00295932] | Phase 1/Phase 2 | 79 participants (Actual) | Interventional | 2005-12-13 | Completed | ||
A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)[NCT01148446] | Phase 3 | 226 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine[NCT00001533] | Phase 1 | 25 participants | Interventional | 1996-09-30 | Completed | ||
Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934] | Phase 3 | 400 participants | Interventional | 2002-01-31 | Completed | ||
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months
Intervention | months (Median) |
---|---|
Sunitinib and Prednisone | 13.1 |
Placebo and Prednisone | 11.8 |
OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
Intervention | percentage of participants (Number) |
---|---|
Sunitinib and Prednisone | 6.1 |
Placebo and Prednisone | 1.8 |
PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
Intervention | weeks (Median) |
---|---|
Sunitinib and Prednisone | 24.1 |
Placebo and Prednisone | 17.9 |
Primary endpoint is best overall response. An evaluable subject classified as a treatment success for the primary endpoint if the subject's best overall response is clinical improvement (CI) as determined by International Working Group Criteria over the first 6 cycles of study treatment. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis - Clinical improvement (CI) in anemia 1/ A minimum 20g/L increase in hemoglobin level or 2. becoming transfusion independent for at least 8 week duration. (NCT00946270)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Group 1 CC-4047 | 0 |
Group 2 | 3 |
Group 3 CC-4047 + Prednisone | 6 |
number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation (NCT00194987)
Timeframe: time of ICH (range 20-40 wks)
Intervention | number of newborns with ICH (Number) |
---|---|
IVIG 1g/kg Twice Per Week | 0 |
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 0 |
Number of Fetal Platelet Counts > 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined (NCT00194987)
Timeframe: 32 +/- 2 weeks
Intervention | number newborns with >50,000 pats (Number) |
---|---|
IVIG 1g/kg Twice Per Week | 44 |
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 43 |
this uses the birth platelet count of the fetuses from the study when they are born (NCT00194987)
Timeframe: 32-40 weeks (the endpoint is the birth which is not at the same number of weeks for all of the babies. This is why the weeks are not listed specifically eg week 40
Intervention | number of newborns with >50,000 pets (Number) |
---|---|
IVIG 1g/kg Twice Per Week | 48 |
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 47 |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 39.1 |
Lenalidomide and Dexamethasone Rd18 | 28.5 |
Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 31.5 |
Lenalidomide and Dexamethasone Rd18 | 21.5 |
Melphalan + Prednisone + Thalidomide (MPT) | 22.1 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 35.0 |
Lenalidomide and Dexamethasone Rd18 | 22.1 |
Melphalan + Prednisone + Thalidomide (MPT) | 22.3 |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 59.1 |
Lenalidomide and Dexamethasone Rd18 | 62.3 |
Melphalan + Prednisone + Thalidomide (MPT) | 49.1 |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 36.7 |
Lenalidomide and Dexamethasone Rd18 | 28.5 |
Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
Lenalidomide and Dexamethasone Rd18 | 17.2 |
Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
Lenalidomide and Dexamethasone Rd18 | 17.2 |
Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 26.0 |
Lenalidomide and Dexamethasone Rd18 | 21.0 |
Melphalan + Prednisone + Thalidomide (MPT) | 21.9 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 25.5 |
Lenalidomide and Dexamethasone Rd18 | 20.7 |
Melphalan + Prednisone + Thalidomide (MPT) | 21.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | Percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 70.0 |
Lenalidomide and Dexamethasone Rd18 | 69.7 |
Melphalan + Prednisone + Thalidomide (MPT) | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
Lenalidomide and Dexamethasone Rd18 | 81.6 |
Melphalan + Prednisone + Thalidomide (MPT) | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of particpants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
Lenalidomide and Dexamethasone Rd18 | 74.8 |
Melphalan + Prednisone + Thalidomide (MPT) | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 60.5 |
Lenalidomide and Dexamethasone Rd18 | 76.8 |
Melphalan + Prednisone + Thalidomide (MPT) | 57.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 46.2 |
Lenalidomide and Dexamethasone Rd18 | 53.1 |
Melphalan + Prednisone + Thalidomide (MPT) | 45.7 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.7 |
Lenalidomide and Dexamethasone Rd18 | 78.6 |
Melphalan + Prednisone + Thalidomide (MPT) | 67.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | percentage of participants (Number) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 75.1 |
Lenalidomide and Dexamethasone Rd18 | 73.4 |
Melphalan + Prednisone + Thalidomide (MPT) | 62.3 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
Lenalidomide and Dexamethasone Rd18 | 1.8 |
Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | months (Median) |
---|---|
Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
Lenalidomide and Dexamethasone Rd18 | 1.8 |
Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 2.9 | -3.3 | -8.6 | -6.4 | -5.1 | -7.5 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.3 | -5.9 | -9.8 | -7.3 | -8.1 | -1.0 |
Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | -6.2 | -13.5 | -10.5 | -12.2 | -2.6 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -1.7 | 1.8 | 0.9 | -1.2 | -2.8 | -2.6 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.2 | -0.7 | -0.9 | -1.6 | -2.2 | -4.9 |
Melphalan + Prednisone + Thalidomide (MPT) | -1.8 | -1.5 | -0.3 | -0.6 | -0.7 | -7.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 6.3 | 0.0 | -5.1 | -5.2 | -5.9 | -7.5 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 8.3 | 1.8 | -2.4 | -2.4 | -4.5 | -7.9 |
Melphalan + Prednisone + Thalidomide (MPT) | 18.4 | 13.9 | 6.8 | 3.7 | 0.0 | -2.2 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 2.3 | 3.4 | 6.0 | 9.1 | 10.9 | 6.4 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 3.8 | 3.7 | 8.2 | 11.8 | 14.8 | 10.8 |
Melphalan + Prednisone + Thalidomide (MPT) | -0.6 | -2.4 | -2.2 | -2.5 | -1.7 | -0.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 3.6 | -1.9 | -2.9 | -1.6 | 2.9 | 0.8 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.9 | -0.8 | -2.3 | -3.5 | -1.8 | -1.0 |
Melphalan + Prednisone + Thalidomide (MPT) | 4.2 | 2.0 | 0.1 | -1.6 | 0.4 | 7.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 0.1 | 3.9 | 5.8 | 4.9 | 3.1 | 3.7 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.6 | 3.8 | 4.6 | 4.6 | 5.8 | 2.6 |
Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 2.1 | 5.5 | 5.1 | 5.1 | -0.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 4.4 | -3.4 | -5.9 | -2.3 | 0.1 | -1.6 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.6 | -2.5 | -3.7 | -4.3 | -3.1 | 0.3 |
Melphalan + Prednisone + Thalidomide (MPT) | 2.8 | -1.8 | -4.5 | -3.9 | -4.3 | 2.7 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -0.3 | -0.4 | -0.3 | 1.6 | 1.8 | 0.5 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 1.9 | 1.4 | 0.4 | 2.0 | 1.9 |
Melphalan + Prednisone + Thalidomide (MPT) | 0.5 | 1.9 | 0.7 | 1.1 | 0.4 | 5.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 3.2 | -1.3 | -1.9 | 1.1 | 1.4 | -1.6 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 0.2 | -1.2 | -1.0 | -0.5 | -5.2 |
Melphalan + Prednisone + Thalidomide (MPT) | -10.5 | -8.9 | -11.6 | -9.6 | -6.0 | -4.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -0.5 | -2.5 | -4.0 | -3.6 | -2.7 | -4.2 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 | -1.1 | -1.3 | -2.2 | -2.3 | 0.4 |
Melphalan + Prednisone + Thalidomide (MPT) | 4.0 | -1.2 | -3.9 | -3.9 | -3.9 | 1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -4.4 | -13.1 | -16.1 | -14.7 | -12.4 | -7.9 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -5.4 | -13.4 | -14.4 | -14.0 | -14.4 | -8.0 |
Melphalan + Prednisone + Thalidomide (MPT) | -7.8 | -12.1 | -13.4 | -14.3 | -14.7 | -6.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -1.4 | 4.7 | 7.6 | 7.4 | 6.8 | 3.0 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.7 | 3.4 | 4.7 | 5.0 | 6.9 | -0.1 |
Melphalan + Prednisone + Thalidomide (MPT) | -0.9 | 2.2 | 5.3 | 6.9 | 8.3 | -0.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -4.6 | 6.3 | 8.6 | 9.4 | 9.1 | 3.8 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -2.7 | 2.4 | 6.3 | 7.8 | 8.0 | -0.3 |
Melphalan + Prednisone + Thalidomide (MPT) | -2.4 | 4.1 | 8.2 | 11.8 | 14.5 | -1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -2.2 | 2.0 | 5.2 | 3.8 | 3.2 | 2.7 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.3 | 0.7 | 4.0 | 2.9 | 4.2 | -1.2 |
Melphalan + Prednisone + Thalidomide (MPT) | -1.4 | 2.4 | 3.4 | 5.8 | 6.0 | -3.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Study discontinuation | |
Lenalidomide and Dexamethasone Rd18 | -1.3 | 4.7 | 5.4 | 3.2 | 5.7 | 5.0 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.4 | 4.8 | 5.9 | 4.8 | 6.4 | -0.1 |
Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 4.3 | 6.1 | 6.5 | 4.8 | 0.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -1.5 | 0.8 | 1.5 | -0.4 | -0.3 | 1.8 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.5 | -1.7 | -1.4 | -1.4 | -2.3 | -5.6 |
Melphalan + Prednisone + Thalidomide (MPT) | -1.6 | -3.0 | -2.8 | -2.6 | -1.1 | -5.6 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -4.1 | -10.0 | -9.9 | -8.7 | -6.2 | -4.5 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.0 | -9.1 | -8.8 | -7.8 | -8.7 | -3.5 |
Melphalan + Prednisone + Thalidomide (MPT) | -4.4 | -7.0 | -7.9 | -6.5 | -7.9 | -3.7 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 3.9 | 9.2 | 12.3 | 12.1 | 11.7 | 8.8 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 4.7 | 8.5 | 9.8 | 10.8 | 12.7 | 5.8 |
Melphalan + Prednisone + Thalidomide (MPT) | 3.3 | 6.3 | 8.0 | 10.0 | 9.5 | 3.2 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | 4.0 | 1.2 | -0.4 | 1.2 | 2.3 | -1.0 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.5 | 1.0 | 1.7 | 1.9 | 2.2 | 0.6 |
Melphalan + Prednisone + Thalidomide (MPT) | 5.6 | 3.5 | 2.9 | 4.7 | 4.3 | 3.8 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
Lenalidomide and Dexamethasone Rd18 | -0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
Melphalan + Prednisone + Thalidomide (MPT) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≥ 1 adverse event (AE) | ≥ 1 grade (Gr) 3 or 4 AE | ≥ 1 grade (Gr) 5 AE | ≥ 1 serious adverse event (SAE) | ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | ≥ 1 AE related to Lenalidomide | ≥ 1 AE related to dexamethasone | ≥ 1 AE related to melphalan | ≥ 1 AE related to prednisone | ≥ 1 AE related to thalidomide | ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 grade 3 or 4 AE related to Lenalidomide | ≥ 1 grade 3 or 4 AE related to dexamethasone | ≥ 1 grade 3 or 4 AE related to melphalan | ≥ 1 grade 3 or 4 AE related to prednisone | ≥ 1 grade 3 or 4 AE related to Thalidomide | ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Lenalidomide | ≥ 1 Grade 5 AE related to Dexamethasone | ≥ 1 Grade 5 AE related to melphalan | ≥ 1 Grade 5 AE related to prednisone | ≥ 1 Grade 5 AE related to Thalidomide | ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | ≥1 SAE related to Len/Dex/Mel/Pred/Thal | ≥1 SAE related to Lenalidomide | ≥1 SAE related to dexamethasone | ≥1 SAE related to melphalan | ≥1 SAE related to prednisone | ≥1 SAE related to thalidomide | ≥1 SAE related to Len/Dex or Mel/Pred/Thal | ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | ≥1 AE leading to Lenalidomide withdrawal | ≥1 AE leading to dexamethasone withdrawal | ≥1 AE leading to melphalan withdrawal | ≥1 AE leading to prednisone withdrawal | ≥1 AE leading to Thalidomide withdrawal | ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | ≥1 AE leading to Lenalidomide reduction | ≥1 AE leading to dexamethasone reduction | ≥1 AE leading to melphalan reduction | ≥1 AE leading to prednisone reduction | ≥1 AE leading to thalidomide reduction | ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | ≥1 AE leading to Rd or MPT interruption | ≥1 AE leading to Lenalidomide interruption | ≥1 AE leading to dexamethasone interruption | ≥1 AE leading to melphalan interruption | ≥1 AE leading to prednisone interruption | ≥1 AE leading to Thalidomide interruption | ≥1 AE leading to Len and Dex or MPT interruption | |
Lenalidomide and Dexamethasone Rd18 | 536 | 433 | 36 | 308 | 501 | 481 | 410 | 0 | 0 | 0 | 269 | 326 | 290 | 177 | 0 | 0 | 0 | 104 | 11 | 9 | 7 | 0 | 0 | 0 | 5 | 158 | 130 | 97 | 0 | 0 | 0 | 64 | 109 | 93 | 104 | 0 | 0 | 0 | 84 | 214 | 155 | 118 | 0 | 0 | 0 | 20 | 321 | 301 | 280 | 0 | 0 | 0 | 241 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 529 | 453 | 50 | 359 | 506 | 482 | 429 | 0 | 0 | 0 | 269 | 373 | 342 | 229 | 0 | 0 | 0 | 131 | 17 | 12 | 16 | 0 | 0 | 0 | 11 | 195 | 165 | 130 | 0 | 0 | 0 | 95 | 157 | 109 | 152 | 0 | 0 | 0 | 96 | 279 | 203 | 170 | 0 | 0 | 0 | 30 | 368 | 353 | 319 | 0 | 0 | 0 | 290 |
Melphalan + Prednisone + Thalidomide (MPT) | 539 | 480 | 38 | 270 | 527 | 0 | 0 | 441 | 326 | 493 | 145 | 423 | 0 | 0 | 307 | 118 | 316 | 49 | 10 | 0 | 0 | 6 | 5 | 5 | 2 | 142 | 0 | 0 | 75 | 62 | 94 | 27 | 153 | 0 | 0 | 83 | 78 | 146 | 71 | 348 | 0 | 0 | 199 | 47 | 254 | 2 | 419 | 0 | 0 | 328 | 324 | 388 | 249 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | participants (Number) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline Grade | Grade 4 Baseline to Grade 1 postbaseline Grade | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline Grade to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
Lenalidomide and Dexamethasone Rd18 | 133 | 85 | 109 | 71 | 30 | 6 | 11 | 15 | 30 | 4 | 0 | 1 | 11 | 18 | 5 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 103 | 96 | 121 | 70 | 21 | 7 | 8 | 17 | 25 | 9 | 1 | 1 | 14 | 18 | 9 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
Melphalan + Prednisone + Thalidomide (MPT) | 37 | 79 | 128 | 141 | 45 | 2 | 2 | 11 | 20 | 21 | 0 | 1 | 7 | 21 | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | participants (Number) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CrCl< 30 mL/min to CrCl< 30 mL/min | CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl< 30 mL/min to ≥ 80 mL/min | CrCl≥ 30 but < 50 mL/min to < 30 mL/min | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | CrCl ≥ 80 mL/min to CrCl< 30 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | |
Lenalidomide and Dexamethasone Rd18 | 17 | 14 | 8 | 2 | 2 | 41 | 55 | 12 | 0 | 1 | 130 | 99 | 1 | 0 | 10 | 114 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 15 | 18 | 7 | 2 | 1 | 37 | 67 | 9 | 0 | 4 | 112 | 107 | 0 | 0 | 6 | 109 |
Melphalan + Prednisone + Thalidomide (MPT) | 19 | 19 | 5 | 0 | 0 | 41 | 65 | 2 | 0 | 4 | 102 | 97 | 0 | 0 | 9 | 121 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | participants (Number) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade 1 Baseline to Grade 1 postbaseline | Grade1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline | Grade 4 Baseline to Grade 1 postbaseline | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
Lenalidomide and Dexamethasone Rd18 | 10 | 30 | 8 | 1 | 0 | 0 | 126 | 123 | 17 | 5 | 0 | 12 | 135 | 41 | 9 | 0 | 1 | 4 | 8 | 3 | 0 | 0 | 0 | 1 | 1 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 6 | 39 | 8 | 0 | 0 | 0 | 106 | 128 | 25 | 2 | 0 | 8 | 125 | 48 | 4 | 0 | 0 | 12 | 10 | 5 | 0 | 0 | 0 | 0 | 1 |
Melphalan + Prednisone + Thalidomide (MPT) | 9 | 25 | 4 | 1 | 0 | 0 | 110 | 123 | 20 | 4 | 0 | 14 | 133 | 47 | 11 | 0 | 0 | 10 | 10 | 2 | 0 | 0 | 1 | 0 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Intervention | participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade1 Baseline to Normal postbaseline Grade | Grade 1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline Grade | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline Grade | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | |
Lenalidomide and Dexamethasone Rd18 | 197 | 211 | 30 | 12 | 5 | 3 | 38 | 19 | 12 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
Lenalidomide and Low-Dose Dexamethasone (Rd) | 197 | 216 | 24 | 15 | 4 | 1 | 34 | 15 | 10 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
Melphalan + Prednisone + Thalidomide (MPT) | 165 | 208 | 27 | 31 | 11 | 6 | 51 | 7 | 10 | 1 | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 0 |
Time to response defined as the time from start of therapy until the response criteria are fulfilled. Response duration defined as the time from response until relapse (progressive disease) or death. (NCT00352794)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Lenalidomide + Prednisone | 14 |
Complete response is transfusion independence with hemoglobin >9 gm/dl; partial response is transfusion dependence with hemoglobin < 9gm/dl with an increase in reticulocyte count over baseline (NCT01464164)
Timeframe: 9 months
Intervention | Participants (Count of Participants) |
---|---|
Sotatercept Cohort 1 | 0 |
Sotatercept Cohort 2 | 0 |
Sotatercept Cohort 3 | 0 |
Sotatercept With Prednisone Boost Cohort 4a | 0 |
Sotatercept Cohort 4b | 0 |
Sotatercept With Prednisone Boost Cohort 5a | 0 |
Sotatercept Cohort 5b | 0 |
Assess severity of adverse events and relationship to sotatercept according to the currently active minor version of the NCI Common Terminology for Adverse Events version 4.0 (NCT01464164)
Timeframe: 9 months
Intervention | Participants (Count of Participants) |
---|---|
Sotatercept Cohort 1 | 0 |
Sotatercept Cohort 2 | 0 |
Sotatercept Cohort 3 | 0 |
Sotatercept With Prednisone Boost Cohort 4a | 0 |
Sotatercept Cohort 4b | 0 |
Sotatercept With Prednisone Boost Cohort 5a | 0 |
Sotatercept Cohort 5b | 0 |
Toxicity assessed using NCI-CTC v. 3.0 (NCT00295932)
Timeframe: 2 years
Intervention | Participants (Count of Participants) |
---|---|
1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide | 4 |
1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide | 6 |
1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide | 3 |
1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide | 4 |
Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid | 2 |
Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid | 18 |
Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham | 3 |
Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami | 4 |
Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham | 10 |
Weekly Bortezomib Dosing Schedule | 12 |
Twice-weekly Bortezomib Dosing Schedule | 13 |
Maximum tolerated dose of Bortezomib in combination with Rituximab, Cyclophosphamide and Prednisone in Phase I participants (NCT00295932)
Timeframe: 2 years
Intervention | mg/m^2 of Bortezomib (Number) | |
---|---|---|
Weekly Bortezomib | Twice-Weekly Bortezomib | |
Arm I | 1.8 | 1.5 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
Intervention | Percentage of Participants (Number) |
---|---|
FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
Intervention | Percentage of Participants (Number) |
---|---|
FCR With Lenalidomide | 95 |
20 reviews available for prednisone and Anemia
Article | Year |
---|---|
Celiac disease and idiopathic pulmonary hemosiderosis: a literature review of the Lane-Hamilton syndrome.
Topics: Adult; Anemia; Celiac Disease; Child; Hemoptysis; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; L | 2022 |
Persistent Mild Anemia and Hypercalcemia were Ignored as Normal Reaction Secondary to Oral Calcium Supplementation in a Steroid-Dependent Asthma Patient Ultimately Diagnosed as Multiple Myeloma: a Case Report and Literature Review.
Topics: Aged; Anemia; Asthma; Calcium; Diagnosis, Differential; Dietary Supplements; Glucocorticoids; Humans | 2019 |
Pregnancy in renal transplant recipients.
Topics: Anemia; Azathioprine; Cyclosporine; Cytomegalovirus Infections; Female; Herpes Simplex; Humans; Immu | 2013 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Postpartum-acquired haemophilia A: a description of three cases and literature review.
Topics: Adult; Anemia; Autoantibodies; Autoimmune Diseases; Blood Transfusion; Combined Modality Therapy; Cu | 2009 |
Primary effusion anaplastic large cell lymphoma in a patient with long-standing dermatitis herpetiformis and celiac disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Cyclophosphamide; Derm | 2013 |
B19 virus infection in renal transplant recipients.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Viral; Antilymphocyte Serum; Basiliximab; Cyclosporine; | 2003 |
[Retroperitoneal fibrosis, an unrecognized inflammatory disease. Clinical observations and review of the literature].
Topics: Aged; Anemia; Aortic Aneurysm; Female; Humans; Inflammation; Male; Middle Aged; Pain; Prednisone; Pr | 2003 |
[APLASTIC ANEMIA IN CHILDREN AND ITS THERAPY].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Aplastic; Child; D | 1964 |
Successful combination of antifungal agents and surgical resection for pulmonary aspergillosis in a child with Hodgkin disease: review of the literature.
Topics: Adolescent; Amphotericin B; Anemia; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Temporal arteritis: a review and case history.
Topics: Aged; Anemia; Blood Sedimentation; Female; Giant Cell Arteritis; Humans; Prednisone | 1996 |
Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation?
Topics: Adolescent; Adult; Anemia; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Hum | 1997 |
Treatment of multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplanta | 1999 |
[Adult Still's disease: study of a series of 11 cases].
Topics: Adult; Anemia; Diagnosis, Differential; Exanthema; Female; Ferritins; Fever; Humans; Incidence; Infe | 2002 |
Diagnosis and management of multiple myeloma and related disorders.
Topics: Alkylating Agents; Amyloidosis; Anemia; Anemia, Refractory; Animals; Antibodies, Monoclonal; Antineo | 1986 |
Multiple myeloma: current therapy and a glimpse of the future.
Topics: Acute Kidney Injury; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 1985 |
Exofoliative dermatitis (erythroderma).
Topics: Adrenal Cortex Hormones; Adult; Anemia; Blood Proteins; Body Temperature Regulation; Cardiac Output; | 1972 |
Steroid therapy of multiple myeloma and macroglobulinemia.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic, Autoimmune; Blood U | 1973 |
[Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases].
Topics: Adrenal Cortex Hormones; Adult; Androgens; Anemia; Busulfan; Drug Synergism; Female; Humans; Leukocy | 1968 |
The treatment of chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Anemia; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Ag | 1969 |
29 trials available for prednisone and Anemia
Article | Year |
---|---|
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Topics: Administration, Oral; Aged; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2019 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di | 2014 |
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferativ | 2014 |
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Hu | 2014 |
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosp | 2016 |
Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
Topics: Anemia; Blood Group Antigens; Female; Hemoglobins; Humans; Immunoglobulins, Intravenous; Mothers; Pr | 2016 |
Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Topics: Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Prescho | 2016 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Hu | 2009 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Lin | 2009 |
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P | 2009 |
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami | 2010 |
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boro | 2011 |
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2012 |
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Bleomycin; Carbopl | 2012 |
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; | 2012 |
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Ant | 2003 |
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami | 2003 |
Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; | 1983 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2000 |
Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
Topics: Aged; Aging; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2001 |
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 1977 |
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 1977 |
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 1977 |
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 1977 |
Prognostic factors in multiple myeloma.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Immunoglobulins; Male; Melph | 1975 |
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic | 1985 |
Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms.
Topics: Acute Disease; Anemia; Antivenins; Blood Coagulation; Cerebral Hemorrhage; Codeine; Epinephrine; Fib | 1974 |
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Anemia; Chemical and Drug Induced Liver Injury; | 1974 |
204 other studies available for prednisone and Anemia
Article | Year |
---|---|
Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course.
Topics: Adult; Anemia; Anti-Inflammatory Agents; Budesonide; Chronic Disease; Enteritis; Eosinophilia; Femal | 2021 |
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Topics: Anemia; Danazol; Hemoglobins; Humans; Myeloproliferative Disorders; Nitriles; Pilot Projects; Predni | 2022 |
[The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis].
Topics: Acidosis, Lactic; Acidosis, Renal Tubular; Anemia; Antineoplastic Agents; Biopsy; Creatinine; Erythr | 2020 |
Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug A | 2020 |
Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2019 |
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr | 2019 |
Risk factors for development of early infectious and noninfectious complications in systemic lupus erythematosus patients undergoing major surgery.
Topics: Adolescent; Adult; Aged; Anemia; Aspirin; Child; Elective Surgical Procedures; Female; Humans; Logis | 2018 |
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Ag | 2019 |
Disseminated histoplasmosis: a cause of hemophagocytic syndrome.
Topics: Adult; Anemia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Asthma; Bone Marrow Cells; Erythroid | 2013 |
Systemic mastocytosis accompanied by a non-secretory plasma cell dyscrasia and nephrotic syndrome-level proteinuria in a 76-year-old patient.
Topics: Aged; Amyloidosis; Anemia; Biopsy; Bone Marrow; Clone Cells; Coloring Agents; Congo Red; Darbepoetin | 2014 |
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Topics: Adult; Aged; Anemia; Danazol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mi | 2014 |
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
Topics: Adult; Anemia; Black or African American; Cohort Studies; Cost-Benefit Analysis; Female; Health Care | 2015 |
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi | 2014 |
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Topics: Aged; Anemia; Anti-Inflammatory Agents; Bone Marrow; Erythrocyte Indices; Female; Humans; Immunosupp | 2016 |
[Systemic lupus erythematosus presenting as Stevens-Johnson syndrome].
Topics: Adult; Anemia; Arthralgia; Autoantibodies; Complement C3; Critical Care; Facial Dermatoses; Female; | 2015 |
Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi | 2015 |
Severe Alveolar Hemorrhage - What's in it for the Gastroenterologist?
Topics: Anemia; Biopsy; Celiac Disease; Diet, Gluten-Free; Endoscopy, Gastrointestinal; Female; Glucocortico | 2016 |
[Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review].
Topics: Anemia; Autoimmune Diseases; Cleft Palate; Cyclophosphamide; DiGeorge Syndrome; Face; Female; Follow | 2016 |
Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report.
Topics: Acitretin; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2008 |
A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
Topics: Analysis of Variance; Anemia; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cholesterol; C | 2009 |
Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.
Topics: Anemia; Antibodies; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Erythropoietin; Hemat | 2010 |
Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha.
Topics: Adult; Anemia; Antiviral Agents; Arthritis; Glucocorticoids; Hepatitis C, Chronic; Humans; Interfero | 2010 |
Eruptive neutrophilic xanthomas.
Topics: Acyclovir; Anemia; Clobetasol; Colchicine; Dermatitis; Humans; Male; Middle Aged; Neutrophils; Predn | 2010 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Ble | 2010 |
Diamond-Blackfan anemia, ribosome and erythropoiesis.
Topics: Anemia; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Chromosomes, H | 2010 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Ant | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2012 |
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T | 2013 |
Prenatal suspicion of Kaposiform hemangioendo-thelioma in siblings: different clinical manifestation and emergency relief.
Topics: Anemia; Anti-Inflammatory Agents; Blood Transfusion, Intrauterine; Cesarean Section; Diagnosis, Diff | 2012 |
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T | 2013 |
Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Community Health Services; Cyclophosph | 2002 |
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2003 |
Prednisone (meticorten) in treatment of acquired hemolytic anemia; preliminary report.
Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Steroids; Tracheophyta | 1956 |
[Prednisone and hemopathy].
Topics: Anemia; Anemia, Hemolytic; Hodgkin Disease; Humans; Leukemia; Prednisone; Steroids | 1955 |
Use of prednisone in the management of some hemorrhagic states.
Topics: Anemia; Anemia, Aplastic; Hemophilia A; Humans; Leukemia; Prednisone; Purpura; Purpura, Thrombocytop | 1956 |
[Prednisone therapy of acquired hemolytic anemia].
Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Tracheophyta | 1957 |
[Prednisone therapy of chronic erythroblastophthisis].
Topics: Anemia; Anemia, Aplastic; Child; Humans; Infant; Prednisone | 1957 |
Treatment of symptomatic hemolytic anemia with prednisone.
Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone | 1957 |
[Physiopathological findings on 2 cases of Cooley's anemia (talasanemia major) treated with prednisone].
Topics: Anemia; beta-Thalassemia; Erythroblasts; Humans; Prednisone; Tracheophyta | 1957 |
[Hemolytic anemia caused by autoantibodies treated with prednisone and splenectomy].
Topics: Anemia; Anemia, Hemolytic; Autoantibodies; Humans; Prednisone; Spleen; Splenectomy; Tracheophyta | 1957 |
Acquired haemolytic anaemia.
Topics: Anemia; Anemia, Hemolytic; Child; Humans; Infant; Prednisone | 1957 |
[Prednisone treatment of auto-immune hemolytic anemia].
Topics: Anemia; Anemia, Hemolytic; Prednisone; Tracheophyta | 1957 |
Acquired haemolytic anemia (clinical case).
Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Tracheophyta | 1957 |
Observations on vitamin B12 absorption in primary pernicious anemia during administration of adrenocortical steroids.
Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12 | 1958 |
Effect of prednisolone on anaemia associated with macroglobulinemia.
Topics: Anemia; Globulins; Humans; Prednisolone; Prednisone; Serum Globulins; Waldenstrom Macroglobulinemia | 1958 |
Red-cell aplasia and benign thymoma; studies on a case responding to prednisone.
Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Thymoma | 1959 |
The mechanism of the prednisone effect upon B12 absorption in pernicious anaemia.
Topics: Anemia; Anemia, Pernicious; Biochemical Phenomena; Humans; Prednisone; Tracheophyta; Vitamin B 12 | 1960 |
[Mechanism of the prednisone effect on vitamin B12 absorption in pernicious anemia].
Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12 | 1960 |
[Associated androgen therapy and corticotherapy (Shahidi-Diamond method) in Fanconi's anemia].
Topics: Anemia; Anemia, Aplastic; Diamond; Fanconi Anemia; Hormone Replacement Therapy; Humans; Prednisone; | 1960 |
[Total remission after prednisone and tetracycline therapy in a case of megaloblastic anemia resistant to liver extracts and vitamin B12].
Topics: Anemia; Anemia, Megaloblastic; Anti-Bacterial Agents; Humans; Liver Extracts; Prednisone; Tetracycli | 1959 |
[Treatment of some infantile hemopathies with prednisone and prednisolone].
Topics: Anemia; beta-Thalassemia; Child; Humans; Infant; Leukemia; Prednisolone; Prednisone | 1959 |
[Acquired hemolytic anemia: clinical course and evaluation of the effectiveness of prednisone therapy in a case followed-up for 4 years].
Topics: Anemia; Anemia, Hemolytic; Prednisone | 1961 |
Aplastic anemia treated with anabolic steroids and corticosteroids.
Topics: Anemia; Anemia, Aplastic; Glucocorticoids; Humans; Prednisone; Steroids; Testosterone Congeners | 1961 |
Remission of hypoplastic anemia in an adult following combined androgen and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Anatomy; Androgens; Anemia; Anemia, Aplastic; Fluoxymesterone; Human | 1962 |
[Drug treatment of acquired hemolytic anemia].
Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Blood Transfusion; Humans; Mercaptopurine; P | 1963 |
Current concepts in therapy. Hemolytic anemia.
Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Chelating Agents; Cortisone; Erythropoiesis; | 1963 |
Autoimmune hemolytic anemia in a 6-week-old child.
Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoimmune Di | 1962 |
Reactivation of pulmonary tuberculosis following steroid therapy for aplastic anemia.
Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
FAMILIAL VITAMIN B12 MALABSORPTION.
Topics: Anemia; Anemia, Macrocytic; Child; Cobalt Isotopes; Genetics, Medical; Hematinics; Humans; Infant; M | 1963 |
[OBSERVATIONS ON THE USE OF TESTOSTERONE IN APLASTIC ANEMIA IN ADULT SUBJECTS].
Topics: Adult; Anemia; Anemia, Aplastic; Humans; Prednisone; Testosterone | 1963 |
CONGENITAL HYPOPLASTIC ANAEMIA: A CASE REPORT.
Topics: Anemia; Anemia, Aplastic; Anemia, Hypoplastic, Congenital; Genetics, Medical; Hemoglobinometry; Huma | 1963 |
CYCLIC HAEMOLYTIC ANAEMIA SYNCHRONOUS WITH PEL-EBSTEIN FEVER IN A CASE OF HODGKIN'S DISEASE.
Topics: Anemia; Anemia, Hemolytic; Antineoplastic Agents; Blood Transfusion; Bronchopneumonia; Fever; Hodgki | 1963 |
[IDIOPATHIC PULMONARY HEMOSIDEROSIS].
Topics: Anemia; Biopsy; Child; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; Infant; Lung Diseases; Predn | 1963 |
CONGENITAL CYSTS OF THE RENAL MEDULLA. A CASE WITH SEVERE REFRACTORY ANEMIA.
Topics: Adolescent; Anemia; Anemia, Aplastic; Anemia, Refractory; Biopsy; Bone Marrow Examination; Child; Cy | 1964 |
[ON HYPERGLOBULINEMIC PURPURA AND ACQUIRED HEMOLYTIC ANEMIA IN THE SAME PATIENT].
Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Purpura; Purpura, Hyperglobulinemic; Tuberculosis | 1963 |
EFFECT OF CORTICOSTEROID THERAPY ON FIBRINOLYSIS IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY CONDITIONS.
Topics: Addison Disease; Adenoma; Adenoma, Chromophobe; Adrenocorticotropic Hormone; Anemia; Anemia, Aplasti | 1964 |
APLASTIC ANEMIA IN PREGNANCY: REPORT OF A CASE.
Topics: Anemia; Anemia, Aplastic; Blood Cell Count; Bone Marrow Examination; Colistin; Erythromycin; Female; | 1964 |
[BENZENE BLOOD DISEASE. 3 CASES OF CHRONIC BENZENE POISONING OF WHICH 2 WERE FATAL (ACUTE LEUKEMIA, ACUTE PANMYELOPHTHISIS)].
Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Myelophthisic; Anti-Bacterial Agents; Ascorbic Acid; Be | 1963 |
THROMBOEMBOLIC PHENOMENA IN ULCERATIVE COLITIS. TWO CASE REPORTS.
Topics: Anemia; Anemia, Hemolytic; Autoimmune Diseases; Blood Coagulation; Chlordiazepoxide; Colitis; Coliti | 1964 |
[PULMONARY IDIOPATHIC HEMOSIDEROSIS, LITTLE KNOWN ETIOLOGY OF CHRONIC POSTHEMORRHAGIC ANEMIA].
Topics: Anemia; Anemia, Hypochromic; Anemia, Sideroblastic; Bone Marrow Examination; Child; Cytodiagnosis; G | 1963 |
[CONGENITAL HYPOPLASTIC STATE OF THE HEMATOPOIETIC SYSTEM IN CHILDREN].
Topics: Anemia; Anemia, Aplastic; Ascorbic Acid; Bilirubin; Blood Cell Count; Blood Chemical Analysis; Blood | 1963 |
[CASE OF SEVERE HYPERAZOTEMIC HEMOLYTIC JAUNDICE WITH FAVORABLE DEVELOPMENT IN A NEWBORN CHILD].
Topics: Anemia; Anemia, Hemolytic; Blood Transfusion; Child; Erythrocytes; Humans; Infant; Infant, Newborn; | 1963 |
APLASTIC ANAEMIA TREATED BY TRANSPLANTATION OF ISOLOGOUS BONE MARROW.
Topics: Anabolic Agents; Anemia; Anemia, Aplastic; Bone Marrow; Bone Marrow Transplantation; Bronchitis; Chl | 1964 |
WEEKLY HIGH-DOSAGE GLUCOCORTICOSTEROID TREATMENT OF LYMPHOCYTIC LEUKEMIAS AND LYMPHOMAS.
Topics: Anemia; Anemia, Hemolytic; Betamethasone; Chlorambucil; Dexamethasone; Geriatrics; Humans; Leukemia; | 1964 |
[PROBLEM OF DIAGNOSIS AND THERAPY IN THROMBOTIC THROMBOCYTOPENIC PURPURA (MOSCOWITZ'S SYNDROME)].
Topics: Anemia; Anemia, Hemolytic; Autopsy; Child; Cortisone; Electrocardiography; Epistaxis; Hematemesis; H | 1964 |
[MICROANEURYSMS OF THE VASCULAR FIELD OF THE BULBAR CONJUNCTIVA IN INTERNAL PATHOLOGY. BIOMICROSCOPIC STUDY].
Topics: Anemia; Anemia, Sickle Cell; Aneurysm; Arteriosclerosis; Conjunctiva; Diabetic Angiopathies; Eye Man | 1964 |
[PANMYELPHTHISIS AND ANTI-CHLOROMYCETIN ANTIBODIES].
Topics: Anemia; Anemia, Aplastic; Cerebral Hemorrhage; Child; Chloramphenicol; Drug Hypersensitivity; Predni | 1964 |
[CONGENITAL HYPOPLASTIC ERYTHROID ANEMIA IN INFANTS].
Topics: Anemia; Anemia, Diamond-Blackfan; Blood Transfusion; Hematopoietic System; Humans; Infant; Prednison | 1964 |
[COMPARATIVE PROGNOSTIC VALUE OF STERNAL PUNCTURE AND MEDULLARY BIOPSY IN THE CLINICAL AND HEMATOLOGICAL STUDY OF 52 CASES OF MEDULLARY INSUFFICIENCY].
Topics: Anemia; Anemia, Aplastic; Biopsy; Bone Marrow; Bone Marrow Examination; Diagnosis; Humans; Pathology | 1964 |
BONE-MARROW TRANSPLANT IN AN IDENTICAL TWIN.
Topics: Allergy and Immunology; Anabolic Agents; Anemia; Anemia, Aplastic; Blood Transfusion; Bone Marrow; B | 1964 |
PRESENT-DAY MANAGEMENT OF RHEUMATOID ARTHRITIS.
Topics: Anemia; Arthritis; Arthritis, Rheumatoid; Climate; Diet; Diet Therapy; Exercise Therapy; Gold; Hot T | 1964 |
[AUTOIMMUNE HEMOLYTIC ANEMIA IN AN INFANT].
Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoimmune Di | 1963 |
CASE HISTORIES FROM THE STAFF CONFERENCES OF THE SLOANE HOSPITAL.
Topics: Accidents; Accidents, Occupational; Anemia; Anemia, Aplastic; Hepatitis; Hepatitis A; Hepatitis B vi | 1964 |
CONGENITAL HYPOPLASIA OF THE EXOCRINE PANCREAS.
Topics: Agranulocytosis; Anemia; Biopsy; Child; Congenital Abnormalities; Cystic Fibrosis; Genetics, Medical | 1964 |
THE USE OF CORTICOSTEROIDS IN NON-NEOPLASTIC BLOOD DISORDERS.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Aplastic; Anemia, Hemolytic; A | 1964 |
DRUG-INDUCED BLOOD DYSCRASIAS. I. APLASTIC ANEMIA.
Topics: Acetazolamide; Anemia; Anemia, Aplastic; Anticonvulsants; Benzene; Chloramphenicol; Chlorothiazide; | 1964 |
AUTO-IMMUNE ANTI-D SPECIFICITY IN INFANCY.
Topics: Anemia; Anemia, Hemolytic; Antibodies; Autoimmune Diseases; Blood Group Antigens; Blood Transfusion; | 1964 |
[ON A NEW CASE OF CONGENITAL ERYTHROPOIETIC PORPHYRIA (GHUENTHER'S DISEASE)].
Topics: Anemia; Blood Chemical Analysis; Child; Humans; Liver Function Tests; Pathology; Porphyria, Erythrop | 1963 |
PROLONGED SURVIVAL IN GOODPASTURE'S SYNDROME.
Topics: Anemia; Anemia, Hypochromic; Anti-Glomerular Basement Membrane Disease; Glomerulonephritis; Hemoside | 1964 |
ACUTE PROMYELOCYTIC LEUKAEMIA.
Topics: Anemia; Anemia, Myelophthisic; Blood Cell Count; Blood Sedimentation; Bone Marrow Examination; Hemor | 1964 |
[VACUOLAR MYOPATHY IN DERMATOMYOSITIS (LUPUS ERYTHEMATOSUS)].
Topics: Anemia; Anemia, Aplastic; Anti-Bacterial Agents; Dermatomyositis; Dexamethasone; Humans; Lupus Eryth | 1964 |
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PRESENTING AS APLASTIC ANEMIA IN A CHILD. CASE REPORT WITH EVIDENCE OF DEFICIENT LEUKOCYTE ACETYLCHOLINESTERASE ACTIVITY.
Topics: Acetylcholinesterase; Alkaline Phosphatase; Anemia; Anemia, Aplastic; Biopsy; Blood Transfusion; Bon | 1964 |
THE CONDITION OF ASTHMATIC PATIENTS AFTER DAILY LONG-TERM CORTICOSTEROID TREATMENT.
Topics: Adrenal Cortex Hormones; Anemia; Anemia, Pernicious; Arizona; Asthma; Biopsy; Blood Chemical Analysi | 1964 |
[PATHOGENESIS OF THE MEDULLARY INSUFFICIENCY IN AUTOIMMUNE ERYTHROBLASTIC APLASIA].
Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Bone Mar | 1964 |
PHYTOHAEMAGGLUTININ.
Topics: Anaphylaxis; Anemia; Anemia, Aplastic; Antigen-Antibody Reactions; Blood Transfusion; Bone Marrow Ex | 1964 |
MASSIVE HEMORRHAGE--SCALPS OF NEWBORN INFANTS.
Topics: Anemia; Exchange Transfusion, Whole Blood; Factor VII Deficiency; Factor VIII; Hemophilia B; Hemorrh | 1964 |
HAEMOLYTIC ANAEMIA ASSOCIATED WITH OVARIAN TERATOMA.
Topics: Anemia; Anemia, Hemolytic; Bilirubin; Blood Cell Count; Blood Chemical Analysis; Female; Hemoglobins | 1964 |
[ANEMIA THERAPY IN CHILDHOOD].
Topics: Adolescent; Anemia; Blood Transfusion; Child; Cobalt; Drug Therapy; Humans; Infant; Infant, Newborn; | 1964 |
[HEPARIN THERAPY OF ACQUIRED HEMOLYTIC ANEMIA].
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anticoagulants; Complement System Proteins | 1964 |
ANDROGENIC HORMONE THERAPY IN LYMPHATIC LEUKEMIA.
Topics: Anemia; Anemia, Aplastic; Erythropoiesis; Fluoxymesterone; Hemoglobins; Humans; Leukemia; Leukemia, | 1964 |
RENAL HOMOTRANSPLANTATION IN 24 PATIENTS.
Topics: Anemia; Anemia, Macrocytic; Antineoplastic Agents; Azathioprine; Blood Group Incompatibility; Cadave | 1965 |
PHYTOHAEMAGGLUTININ IN APLASTIC ANAEMIA.
Topics: Anemia; Anemia, Aplastic; Blood Platelets; Blood Transfusion; Hemoglobins; Leukocyte Count; Neutroph | 1964 |
[PURE ERYTHROBLASTOPENIA. APROPOS OF A CASE OF PRIMARY PURE ERYTHROBLASTOPENIA IN AN ADULT].
Topics: Anemia; Anemia, Aplastic; Classification; Diagnosis, Differential; Geriatrics; Humans; Prednisone; R | 1964 |
[STUDIES OF ERYTHROPOIESIS IN CHRONIC HYPOPLASTIC ANEMIA OF THE BLACKFAN-DIAMOND TYPE].
Topics: Anemia; Anemia, Aplastic; Bone Marrow Examination; Child; Erythrocyte Count; Erythropoiesis; Humans; | 1964 |
THE SYNDROME OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
Topics: Acetylcholinesterase; Alkaline Phosphatase; Anemia; Anemia, Hemolytic; Anticoagulants; Australia; Bl | 1964 |
ANEMIA IN RHEUMATIC FEVER.
Topics: Anemia; Anemia, Hemolytic; Aspirin; Blood Cell Count; Child; Drug Therapy; Hematocrit; Hemoglobinome | 1965 |
CHRONIC ERYTHROCYTIC HYPOPLASIA FOLLOWING PERNICIOUS ANEMIA.
Topics: Anemia; Anemia, Aplastic; Anemia, Pernicious; Blood Transfusion; Bone Marrow Examination; Clinical L | 1965 |
CHRONIC ACTIVE ("LUPOID") HEPATITIS; A CLINICAL, SEROLOGICAL, AND PATHOLOGICAL STUDY OF 20 PATIENTS.
Topics: Adolescent; Anemia; Arthritis; Autoantibodies; Blood Protein Disorders; Blood Protein Electrophoresi | 1965 |
AUTO-IMMUNE HEMOLYTIC ANEMIA TREATED WITH D-PENICILLAMINE; REPORT OF A CASE.
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Transfusion; Drug Th | 1965 |
[CIRCULATORY BEHAVIOR IN LEUKOSES WITHOUT AND WITH THERAPY].
Topics: Anemia; Blood Circulation; Blood Transfusion; Drug Therapy; Geriatrics; Humans; Leukemia; Polycythem | 1965 |
PHYTOHAEMAGGLUTININ IN TREATMENT OF APLASTIC ANAEMIA.
Topics: Anemia; Anemia, Aplastic; Busulfan; Injections; Injections, Intravenous; Phenacetin; Phytohemaggluti | 1965 |
PHYTOHAEMAGGLUTININ IN THE TREATMENT OF APLASTIC ANAEMIA.
Topics: Anemia; Anemia, Aplastic; Drug Therapy; Phenylbutazone; Phytohemagglutinins; Plant Lectins; Predniso | 1965 |
APLASTIC ANEMIA FOLLOWING EXPOSURE TO BENZENE HEXACHLORIDE (LINDANE).
Topics: Agranulocytosis; Anemia; Anemia, Aplastic; Child; Chlordan; DDT; Diagnosis; Drug Therapy; Ecchymosis | 1965 |
FAMILIAL AUTO-IMMUNE HEMOLYTIC ANEMIA.
Topics: Anemia; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Coombs Test; Drug Therapy; gamma-Globuli | 1965 |
[Drug-induced aplastic anemia complicated by diabetes mellitus during prednisone therapy].
Topics: Anemia; Anemia, Aplastic; Diabetes Mellitus; Humans; Prednisone; Thiosemicarbazones; Tracheophyta | 1959 |
[Erythropoiesis in Cooley's disease in relation to the administration of prednisone].
Topics: Anemia; beta-Thalassemia; Child; Erythropoiesis; Hematopoiesis; Infant; Prednisone | 1960 |
Effect of prednisone on B12 absorption in pernicious anaemia.
Topics: Anemia; Anemia, Pernicious; Biochemical Phenomena; Humans; Prednisone; Tracheophyta; Vitamin B 12 | 1960 |
[Effects of prednisone on B12 absorption in pernicious anemia].
Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12 | 1959 |
Erythrocyte aplasia and hypogammaglobulinemia. Response to steroids in a young adult.
Topics: Agammaglobulinemia; Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Steroids | 1961 |
Severe hypoplastic anemia. Successful treatment with testosterone and prednisone.
Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Testosterone; Tracheophyta | 1962 |
True or absolute bone marrow failure. A ferrokinetic and therapeutic study.
Topics: Anemia; Anemia, Aplastic; Bone Marrow; Humans; Iron; Prednisone | 1962 |
Unprovoked periodontal hemorrhage, life-threatening anemia and idiopathic thrombocytopenia purpura: an unusual case report.
Topics: Adult; Aminocaproic Acid; Anemia; Antifibrinolytic Agents; Diagnosis, Differential; Gingival Hemorrh | 2003 |
Multiple complications in multiple myeloma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fractures, Spontaneous; Hip Fr | 2005 |
Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine.
Topics: Anemia; Animals; Carcinoma, Squamous Cell; Cyclosporine; Diagnosis, Differential; Dog Diseases; Dogs | 2005 |
[Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2005 |
Masked giant cell arteritis.
Topics: Aged; Anemia; Anti-Inflammatory Agents; Biopsy; Blood Sedimentation; Female; Giant Cell Arteritis; H | 2006 |
[Fatigue, loss of appetite and anuria due to retroperitoneal fibrosis].
Topics: Aged; Anemia; Anti-Inflammatory Agents; Anuria; Diagnosis, Differential; Fatigue; Feeding and Eating | 2007 |
Chronic anemia and thrombocytosis as the initial presentation of Still's disease in an elderly patient.
Topics: Aged; Anemia; Antirheumatic Agents; Chronic Disease; Female; Glucocorticoids; Humans; Methotrexate; | 2007 |
Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.
Topics: Anemia; Drug Therapy, Combination; Erythrocyte Count; Female; Humans; Immunosuppressive Agents; Midd | 2007 |
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
Topics: Anemia; Antibodies; Antiviral Agents; Epoetin Alfa; Erythropoietin; Graft Rejection; Hematinics; Hep | 2007 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Familial leukemia: uncommon type of chronic lymphocytic leukemia in two sisters.
Topics: Agammaglobulinemia; Anemia; Chlorambucil; Female; Humans; Leukemia, Lymphoid; Middle Aged; Prednison | 1982 |
[Angioimmunoblastic lymphadenopathy. Case report].
Topics: Anemia; Body Weight; Female; Fever; Hepatomegaly; Humans; Immunoblastic Lymphadenopathy; Immunosuppr | 1982 |
Long-term assessment of chlorambucil in children with nephrotic syndrome who fail to respond adequately to corticosteroids.
Topics: Adolescent; Anemia; Bacterial Infections; Child; Child, Preschool; Chlorambucil; Drug Resistance; Fe | 1981 |
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Ant | 1994 |
Severe anemia as the presenting manifestation of giant cell arteritis.
Topics: Aged; Anemia; Biopsy; Female; Giant Cell Arteritis; Humans; Male; Prednisone | 1995 |
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive | 1994 |
Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis.
Topics: Aged; Anemia; Calcitriol; Calcium; Creatinine; Cyclophosphamide; Female; Granulomatosis with Polyang | 1994 |
Hypereosinophilic syndrome presenting with diarrhoea and anaemia in a patient with systemic lupus erythematosus.
Topics: Adult; Anemia; Diarrhea; Female; Follow-Up Studies; Glucocorticoids; Humans; Hypereosinophilic Syndr | 1998 |
[A case of post-partum remission of acquired dyserythropoiesis, a rare cause of anemia in disseminated lupus erythematosus].
Topics: Adult; Anemia; Anti-Inflammatory Agents; Cells, Cultured; Erythroid Precursor Cells; Erythropoiesis; | 1998 |
A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Grouping and Cro | 1998 |
Steroid hormone-responsive secondary factor X deficiency.
Topics: Aged; Anemia; Diabetes Mellitus; Factor X Deficiency; Glucocorticoids; Hemorrhage; Humans; Male; Par | 1998 |
Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Dermatologic Agents; Exudates and Transudates | 1999 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 2000 |
Corticosteroid-responsive thrombocytopenia in two beef cows.
Topics: Anemia; Animals; Cattle; Cattle Diseases; Dexamethasone; Epistaxis; Female; Glucocorticoids; Hematom | 2000 |
Light and electron microscopic features of eperythrozoon-like parasites in a North American opossum (Didelphis virginiana).
Topics: Anemia; Animals; Anti-Bacterial Agents; Antinematodal Agents; Blood Chemical Analysis; Doxycycline; | 2000 |
Lupus nephritis in children: prognostic significance of clinicopathological findings.
Topics: Adolescent; Anemia; Blood Pressure; Child; Child, Preschool; Creatinine; Cyclophosphamide; Female; H | 2001 |
Experiences with leflunomide in solid organ transplantation.
Topics: Anemia; Calcineurin Inhibitors; Creatinine; Humans; Immunosuppressive Agents; Isoxazoles; Kidney Tra | 2002 |
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.
Topics: Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2002 |
Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome.
Topics: Amikacin; Anemia; Anti-Bacterial Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; | 2002 |
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
Topics: Anemia; Dapsone; Erythema Nodosum; Hemoglobins; Humans; Leprostatic Agents; Leprosy, Lepromatous; Pr | 2001 |
Anemia associated with feline leukemia virus infection.
Topics: Androgens; Anemia; Animals; Blood Transfusion; Bone Marrow Examination; Cat Diseases; Cats; Leukemia | 1979 |
Immunoblastic lymphadenopathy with purpura and cryoglobulinemia.
Topics: Allopurinol; Anemia; B-Lymphocytes; Cryoglobulins; Female; Humans; Leukopenia; Lymphatic Diseases; M | 1977 |
Multiple myeloma: uncommon or uncommonly diagnosed?
Topics: Adult; Anemia; Blood Sedimentation; Bone Diseases; Female; Humans; Male; Melphalan; Middle Aged; Mul | 1977 |
Acute lymphoblastic leukemia terminating as histiocytic medullary reticulosis.
Topics: Acute Disease; Adult; Anemia; Autopsy; Bone Marrow; Erythrocytes; Hepatomegaly; Humans; Leukemia, Ly | 1975 |
The evolution into and the treatment of late stage polycythemia vera.
Topics: Anemia; Female; Humans; Iron; Male; Phosphorus Radioisotopes; Polycythemia Vera; Prednisone; Primary | 1976 |
Arteritis of the aged (giant cell arteritis) and fever of unexplained origin.
Topics: Aged; Anemia; Blood Sedimentation; Diagnosis, Differential; Female; Fever of Unknown Origin; Giant C | 1976 |
Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Erythroblasts; Erythropoietin; Hodgkin Disea | 1992 |
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality | 1989 |
[Erythroblastopenia associated with chronic myelomonocytic leukemia].
Topics: Aged; Anemia; Bone Marrow; Erythroblasts; Humans; Leukemia, Myelomonocytic, Chronic; Male; Mercaptop | 1989 |
[Crohn's disease in children and adolescents].
Topics: Adolescent; Anemia; Child; Crohn Disease; Drug Therapy, Combination; Female; Growth Disorders; Human | 1985 |
Cyclosporine experience in renal transplantation in children.
Topics: Adolescent; Anemia; Azathioprine; Child; Creatinine; Cyclosporins; Female; Gingival Hyperplasia; Gra | 1987 |
The anemia of sarcoidosis.
Topics: Adult; Anemia; Bone Marrow; Female; Granuloma; Humans; Iron; Leukopenia; Lung Diseases; Male; Predni | 1988 |
Sarcoidosis. Usual and unusual manifestations.
Topics: Anemia; Female; Humans; Hypercalcemia; Liver Diseases; Lung Diseases; Methotrexate; Middle Aged; Pre | 1988 |
Diamond-Blackfan syndrome in adult patients.
Topics: Adult; Aged; Anemia; Blood Transfusion; Bone Marrow; Erythrocyte Count; Erythrocyte Transfusion; Fem | 1985 |
[Whipple's disease. Case report (author's transl)].
Topics: Anemia; Biopsy; Cholecystectomy; Cholelithiasis; Diarrhea; Edema; Humans; Intestinal Mucosa; Jejunum | 1974 |
Case for diagnosis: leukocytoclastic vasculitis.
Topics: Anemia; Arteritis; Blood Sedimentation; Body Weight; Dapsone; Diagnosis, Differential; Humans; Leuko | 1973 |
[Studies on blood mast cell leukemias].
Topics: Alkaline Phosphatase; Anemia; Bone Marrow Examination; Female; Hematoma, Subdural; Hemorrhagic Disor | 1968 |
A heart transplantation. 8. Immunological and haematological aspects.
Topics: ABO Blood-Group System; Anaphylaxis; Anemia; Antibodies; Antilymphocyte Serum; Australia; Azathiopri | 1969 |
[Lymphoid hepatosplenomegaly].
Topics: Adrenal Cortex Hormones; Aged; Anemia; Blood Transfusion; Hepatomegaly; Humans; Leukemia, Lymphoid; | 1968 |
Combination chemotherapy in accelerated phase of chronic granulocytic leukemia.
Topics: Adolescent; Adult; Aged; Anemia; Blood Platelets; Blood Transfusion; Blood Urea Nitrogen; Bone Marro | 1969 |
Alternate-day corticosteroid therapy in juvenile chronic polyarthritis.
Topics: Adolescent; Anemia; Arthritis, Juvenile; Body Height; Child; Child, Preschool; Chronic Disease; Drug | 1974 |
Response to therapy confirms diagnosis.
Topics: Aged; Anemia; Blood Sedimentation; Diuretics; Edema; Female; Hemoglobinometry; Humans; Leukocytosis; | 1973 |
The use of different drugs and combinations in the treatment of Hodgkin's disease.
Topics: Administration, Oral; Anemia; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; I | 1973 |
Corticosteroid therapy in Felty's syndrome and its effect on hypersplenic rats.
Topics: Aged; Anemia; Animals; Body Weight; Chromium Radioisotopes; Disease Models, Animal; Felty Syndrome; | 1974 |
Azathioprine for pemphigus and pemphigoid--a 4 year follow-up.
Topics: Adult; Aged; Anemia; Azathioprine; Bone Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; F | 1974 |
Erythropoietin activity in anephric or renal allotransplanted man.
Topics: Adult; Androgens; Anemia; Animals; Azathioprine; Blood Urea Nitrogen; Bone Marrow; Erythropoietin; F | 1969 |
Renal homotransplantation in children.
Topics: Adaptation, Psychological; Adolescent; Anemia; Azathioprine; Cadaver; Child; Child, Preschool; Cyclo | 1970 |
Combination chemotherapy of Hodgkin's disease in private practice.
Topics: Adolescent; Adult; Aged; Anemia; Biopsy; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mid | 1972 |
[Hematologic therapy of malignant lymphoma].
Topics: Anemia; Blood Platelets; Blood Transfusion; Erythrocytes; Female; Hodgkin Disease; Humans; Lymphoma; | 1971 |
Myelofibrosis with unusual neurologic abnormalities.
Topics: Aged; Ampicillin; Anemia; Blood Platelet Disorders; Bone and Bones; Brain; Dyspnea; Female; Heart; H | 1971 |
Myelofibrosis and myeloid leukaemia.
Topics: Anemia; Biopsy; Blood Transfusion; Child, Preschool; Erythrocyte Count; Hepatomegaly; Humans; Leukem | 1967 |
Treatment of AGL.
Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans | 1969 |
Paroxysmal nocturnal hemoglobinuria terminating in acute granulocytic leukemia.
Topics: Androgens; Anemia; Blood Cell Count; Blood Transfusion; Bone Marrow Examination; Cyclophosphamide; H | 1969 |
Cytarabine.
Topics: Acute Disease; Amino Sugars; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Cell | 1971 |
Agnogenic myeloid metaplasia; its current managment.
Topics: Anemia; Female; Fluoxymesterone; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Splen | 1970 |
Shortened red cell survival in chronic posthaemorrhagic anaemia: effect of iron and prednisone.
Topics: Adolescent; Adult; Aged; Anemia; Blood Volume; Chromium Isotopes; Erythrocyte Aging; Erythropoiesis; | 1970 |
[Effect of therapy on iron metabolism in patients with progressive chronic polyarthritis].
Topics: Anemia; Anemia, Hypochromic; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; B | 1970 |
Osteopetrosis from the ophthalmological point of view. A report of two cases.
Topics: Anemia; Female; Genes, Recessive; Humans; Infant; Male; Optic Atrophy; Optic Nerve; Osteopetrosis; P | 1970 |
Empyema in rheumatoid pleuropulmonary disease.
Topics: Adult; Aged; Anemia; Arthritis, Rheumatoid; Bronchial Fistula; Empyema; Female; Glucose; Humans; Lun | 1971 |
Mu-chain disease.
Topics: Adult; Agammaglobulinemia; Anemia; Bence Jones Protein; Chlorambucil; Female; Fractures, Bone; Heavy | 1971 |
Steroid induced gastric regeneration and functional recovery.
Topics: Achlorhydria; Aged; Anemia; Female; Gastric Mucosa; Hemoglobins; Humans; Prednisone; Regeneration; S | 1967 |
[Fiessinger-Leroy-Reiter's disease in a woman, with cardiac and anemic complications and fatal development].
Topics: Adult; Anemia; Arthritis, Reactive; Female; Humans; Prednisone; Sex Factors; Tachycardia | 1968 |
Effect of artificially induced abacterial erysipelas and of chronic aseptic abscess on human and experimental neoplasms.
Topics: Abscess; Adult; Aged; Amylases; Anemia; Animals; Breast Neoplasms; Child; Erysipelas; Eye Neoplasms; | 1968 |
Abnormal (marker) chromosomes in two patients with acute myelofibrosis.
Topics: Aged; Anemia; Anti-Bacterial Agents; Blood Cell Count; Blood Cells; Blood Chemical Analysis; Blood T | 1969 |
[Retroperitoneal fibrosis. A case with unusual symptomatology].
Topics: Aged; Anemia; Blood Sedimentation; Diagnosis, Differential; Female; Fever; Humans; Polymyalgia Rheum | 1969 |
[Chlorambucil in the treatment of idiopathic nephrotic syndrome without glomrular lesions in childhood. Apropos of 30 cases].
Topics: Adolescent; Anemia; Biopsy; Child; Child, Preschool; Chlorambucil; Female; Glucocorticoids; Humans; | 1969 |
Alkeran and multiple myeloma.
Topics: Anemia; Cyclophosphamide; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Urethane | 1966 |
[Anemia in the course of lymphatic leukemia].
Topics: Anemia; Humans; Leukemia, Lymphoid; Male; Middle Aged; Prednisone; Thrombocytopenia | 1966 |
[On the clinical aspects of essential lung hemosiderosis].
Topics: Anemia; Female; Hemosiderosis; Humans; Lung Diseases; Middle Aged; Prednisone; Pulmonary Heart Disea | 1966 |